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The formation of aberrant disulfide bonds is a structural consideration for the manufacturing 
of the extracellular domain of human CD83 (hCD83ext), a potential therapeutic protein. In 
certain instances, hCD83ext protein products, even when stored frozen, tend to dimerize or 
even multimerize through the formation of aberrant intermolecular disulfide bonds. Herein, 
we discovered an analytical inconsistency and applied a modified sample preparation 
protocol for proper structural analysis of hCD83ext products which are heterologously 
expressed in Escherichia coli and subsequently purified. In addition, a mutant derivative with 
the Cys100Ser mutation was identified as an improved version which did not form dimers or 
multimers. The identification of this mutant variant as a more potent therapeutic protein than 
other hCD83ext species demonstrated that the structural variation associated with disulfide 
bond formation can be a critical issue for rigorous control of the quality and bioactivity of 
therapeutic proteins. The application of this mutant variant for protein therapeutic is currently 
under exploration. 
As a comparative study, the hCD83ext was expressed as a glutathione-S-transferase 
(GST) fusion in two E. coli B strains, i.e. BL21 and Origami B having a reductive and 
oxidative cytoplasm. The final therapeutic products of hCD83ext produced by the two 
expression hosts exhibited significant differences in protein conformation and molecular 
properties, which presumably resulted from different disulfide patterns. The study highlights 
the importance of developing proper host/vector systems and biomanufacturing conditions 
for the production of recombinant therapeutic proteins with a consistent product quality.  
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Cys27 in the hCD83ext was identified as a target for molecular manipulation. Two E. 
coli strains of BL21(DE3) and Origami B(DE3) were used as the expression host to produce 
the Cys27 mutants. It was observed that Cys27 was involved in the in vivo formation of 
intramolecular disulfide bonds when hCD83ext was expressed in Origami B(DE3). The 
Origami-derived protein products had a higher tendency than the BL21-derived counterparts 
for multimerization via the in vitro formation of intermolecular disulfide bonds. Various 
analyses were conducted to identify the structural differences among these mutant variants. 
Most importantly, molecular stability was enhanced by the Cys27 mutations since the Cys27 
mutants derived from either BL21 or Origami were much less susceptible to degradation 
compared to wild-type hCD83ext. This study highlights the implications of aberrant disulfide 
bond formation on the production of therapeutic proteins.  
To address an inconsistent bioactivity issue that is primarily due to the aberrant 
formation of disulfide bonds associated with the presence of five cysteine residues, i.e. AA 
27, 35, 100, 107, and 129, the molecular role that each cysteine plays upon the formation of 
intramolecular or intermolecular disulfide bonds was characterized, using various hCD83ext 
mutant variants derived by two E. coli expression hosts, i.e. BL21(DE3) and Origami 
B(DE3). Among the five cysteines, Cys100 and Cys129 can act as a bridging cysteine for in 
vitro multimerization via the formation of intermolecular disulfide bonds. The 
multimerization can be alleviated to some extent with less free Cys129 residues, associated 
with the possible formation of Cys27-Cys129 intramolecular disulfide bond. As a result, 
introducing the Cys27 mutation can increase the multimerization presumably via freeing more 
Cys129 residues. In addition, protein stability can be improved in the presence of the Cys27 
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mutation. The formation of the Cys27-Cys129 intramolecular disulfide bond appears to be 
more effective in the presence of the Cys100 mutation, resulting in the suppression of 
multimerization. The two conserved cysteine residues, i.e. Cys35 and Cys107, can be 
potentially linked to form an intramolecular disulfide bond, particularly when the protein is 
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10 and 13 / room temperature samples taken on day 20. Panel C: M35, lane 1/ molecular 
weight markers; lanes 2, 4, 6 and 8 / -20 °C samples taken on day 20; lanes 3, 5, 7 and 9 / 
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1.1 Research Background 
Therapeutic proteins continue to play a pivotal role in human healthcare and pharmaceutical 
industry. Approximately 150 therapeutic protein products with a current annual market value 
of US$ 90 billion have been commercialized and at least 500 candidates are under various 
trial stages around the world [3]. While the use of mammalian expression systems for the 
production of therapeutic proteins has gained practical interests over the past decade, the 
Eschercihia coli bacterium retains its popularity as the workhorse primarily due to its well-
characterized genome and mature techniques for genetic manipulation. Its importance is also 
reflected by the fact that 9 out of the 31 therapeutic proteins approved between 2003 and 
2006 are produced in E. coli [3]. A critical issue associated with therapeutic protein 
production is the batch-to-batch consistency of product quality. Since therapeutic protein 
products often undergo extensive storage before being clinically administered, their quality 
can be jeopardized by several protein deformation mechanisms, such as proteolysis, auto-
degradation, misfolding, aggregation, oxidation, and other reactions, even under mild storage 
conditions.  
Dendritic cells (DCs) are antigen presenting cells (APC) that circulate in the 
bloodstream and identify antigens in order to activate specific T cells for that antigen. 
Recently, the use of modified DC for the vaccination of cancer patients presents a promise 
for future development in anti-cancer vaccines. Human CD83 (hCD83) is a 45 kDa 
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glycoprotein expressed on the membrane of DC. Though the precise function of hCD83 is 
not yet known, it serves as a differential marker for mature dendritic cells and possibly 
mediates the display of the T cell’s stimulatory capacity. Structurally, it is a member of the 
immunoglobulin (Ig) superfamily and composed of three domains, i.e. a cytoplasmic domain 
[39 amino acids (AAs)], a short transmembrane domain (22 AAs), and an extracellular Ig-
like domain (125 AAs) (SwissProt Accession No. Q01151). There are three sites (i.e. AAs 
79, 96, and 117) in the extracellular domain for glycosylation. The immunorelated function 
for hCD83 is believed to lie in the extracellular domain, since the hCD83 extracellular 
domain (hCD83ext) could inhibit DC-mediated T cell stimulation [4] and was clinically 
effective in treating autoimmune disorder using the murine experimental autoimmune 
encephalomyelitis (EAE) model [5]. Recently, the soluble form of hCD83ext was proposed 
as a potential therapeutic to treat transplantation rejection and a number of inflammatory and 
autoimmune disorders [4-6]. Currently, it is under preclinical trial conducted by Argos 
Therapeutics, USA (http://www.argostherapeutics/product_pipeline). The availability of 
purified hCD83ext has been crucial for work demonstrating its biological functions and 
applications. For this initiative, a bioprocess to produce recombinant hCD83ext using an E. 
coli expression system was developed [7], because the glycosylation is non-essential for the 
immunosuppressive bioactivity [8].  
The cDNA encoding hCD83ext (i.e. AAs from 20 to 145 of hCD83) was cloned and 
overexpressed as a GST fusion protein (GST-hCD83ext) under the regulation of the tac 
promoter. The expressed GST fusion was captured using GST affinity chromatography and 
subsequently processed with on-column thrombin cleavage to release the hCD83ext moiety 
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as the target protein. Anion exchange chromatography was used to further remove trace 
amount of contaminant proteins and endotoxin from hCD83ext final product. Though very 
pure hCD83ext with low endotoxin level could be produced, inconsistent biological activity 
was encountered. The structural analysis revealed the presence of various disulfide-bonded 
monomeric and multimeric forms in several stored hCD83ext products from independent 
batches. Up to now, the knowledge of the structure of hCD83ext has been very limited. The 
three-dimensional structure or disulfide bond linkage has not yet been experimentally solved. 
There are five cysteine residues (AAs 27, 35, 100, 107, and 129) in the recombinant 
hCD83ext. Theoretically, any one of them can be involved in the intra- or intermolecular 
disulfide bond formation. An intramolecular disulfide bond between Cys35 and Cys107 was 
predicted, and Cys129 was previously reported to be critical for the dimerization [9]. In this 
research, recombinant hCD83ext was used as a target protein to address the consistent quality 
issue during therapeutic protein production.  
 
1.2 Research Objectives 
A comprehensive literature review on recombinant therapeutic protein production as well as 
understanding the structural properties of the target protein, hCD83ext, generated several 
critical aspects that need to be addressed for the manufacturing of hCD83ext with consistent 
quality.  
1. What are critical structural factors leading to the inconsistency of hCD83ext product? 
2. How do the factors influence the structure and molecular properties of hCD83ext? 
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3. What can be done to achieve consistent structure and biological activity of 
hCD83ext? 
Therefore, the objectives of this research are: 
1. Identify the critical factors for the inconsistent structure of hCD83ext. 
2. Investigate the impact of the factors on the molecular properties of hCD8ext. 
3. Elucidate the underlying mechanism by which these factors affect the hCD83ext. 
4. Develop a strategy to modulate the structural properties of hCD83ext during 
bioprocessing. 
 
1.3 Research Approach 
The approach of this thesis is based on a comprehensive examination of the mechanism 
leading to inconsistent quality of therapeutic proteins as well as our theoretical analysis and 
characterization of the structure of hCD83ext.  
Thus, it is hypothesized: 
1. The inconsistent biological activity is associated with the unregulated formation of 
intramolecular and/or intermolecular disulfide bond under oxidative conditions. 
2. The molecular properties are significantly affected by aberrant disulfide bond 
formation.  
3. The presence of free cysteine residues might disrupt disulfide bond pattern via 




1.4 Outline of Thesis 
This thesis comprises eight chapters and is organized as follows: 
Chapter 1 introduces the research background, research objectives as well as the 
hypotheses for the whole thesis.  
Chapter 2 gives a comprehensive literature review on recombinant therapeutic protein 
production. 
Chapter 3 introduces the bioprocess that was developed for production and 
purification of hCD83ext and the established analytical methods for the structure of 
hCD83ext. 
Chapter 4 investigates hCD83ext mutant variants. A more potent therapeutic, mutant 
variant with mutation Cys100Ser (M3) was identified. A protocol for the analysis of disulfide 
bond formation in hCD83ext was established.  
Chapter 5 examines the molecular property of hCD83ext produced by two E. coli host 
strains respectively with reductive and oxidative cytoplasm, demonstrating the impact of the 
in vivo disulfide bond formation. 
Chapter 6 studies two hCD83ext mutant variants with mutation Cys27Ser and 
Cys27Glu, respectively, providing an approach to improve the storage stability of hCD83ext. 
Chapter 7 explores a number of extended mutants of hCD83ext M3 to elucidate the 
roles of five cysteine residues in disulfide bond formation. 
Chapter 8 summarizes the whole thesis and presents conclusions and 






Prior to the advent of modern biotechnology, medical applications involving proteins were 
less appreciated due to their very limited availabilities from natural sources like organs. With 
the development of recombinant DNA technology, therapeutic protein production has entered 
a new era [10]. Theoretically, therapeutic proteins from any biological source can be 
produced at large scale using appropriate gene expression systems. Produced by an E. coli 
expression system, Eli Lilly’s recombinant DNA human insulin was the first officially 
approved recombinant pharmaceutical by the FDA (Food and Drug Administration, USA) in 
1982. By 2006, about 150 therapeutic proteins have been approved in the USA and/or the 
EU, which have demonstrated important impacts on the pharmaceutical industry, diagnosis 
and treatment of various diseases, such as cancer, autoimmune diseases, and metabolic 
disorders. Currently, more than 500 candidate protein drugs are being evaluated in clinical 
trials, and advanced biotechnologies such as genomics, proteomics and high-throughput 
screening definitely will facilitate new drug development [3]. 
 
2.1 Expression Systems for Recombinant Therapeutic Protein 
Production 
The choice of a host expression system is fundamental and critical for recombinant 
therapeutic protein production. Until the mid-90s, E. coli was the dominant host primarily 
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due to the economic competitiveness, a wealth of molecular knowledge, and mature genetic 
manipulation techniques. To date, the most successful cases are the commercialization of 
human insulin (Eli Lilly) and bovine growth hormone (bGH, Monsanto). Impressively, the 
cost of bulk production for bGH has been reduced to less than $5/g [11]. However, the high 
level expression in E. coli frequently results in the intracellular accumulation of insoluble 
aggregates of heterologous proteins (known as inclusion bodies), presumably due to the lack 
of efficient cellular machinery for protein folding. Extra refolding process is needed in 
industry to obtain soluble and bioactive therapeutic protein products. On the other hand, 
inclusion bodies facilitate downstream purification owing to a single low-speed 
centrifugation step after cellular homogenization to recover the inclusion bodies due to their 
high density. Strategies to achieve successful refolding of recombinant proteins from 
inclusion bodies are being continuously advanced [12, 13]. When therapeutic protein 
products require glycosylation for their biological activity, which is the case for 60% of the 
current therapeutic protein market, E. coli expression systems are no longer suitable.  
Driven by the need to produce glycoproteins, mammalian cell production has 
garnered significant attention during the past decade [11, 14]. Mammalian cells possess 
superior capacity for proper protein folding, assembly and post-translational modifications. 
The development of genetic manipulation techniques now allows routine production of 
recombinant therapeutic proteins in such systems. They are the dominant hosts for the 
production of therapeutic proteins requiring specific glycosylation pattern for their biological 
activity. Chinese hamster ovary (CHO) cells and baby hamster kidney (BHK) cells are the 
most popular systems in the industry [10]. The productivity of mammalian cell cultures has 
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been significantly increased through medium composition, bioreactor design, and process 
control. And further improvement is expected along with the advances achieved in vector and 
host cell engineering [15].  
Yeast host systems are also widely used in the pharmaceutical industry. Yeasts can be 
cultivated rapidly and cheaply with well-established scale-up processes. Compared to 
prokaryotic systems, more advanced regulation of post-translational modifications (e.g., 
disulfide bond formation and glycosylation) and more efficient secretion are offered. The 
best genetically characterized species Saccharomyces cerevisiae is by far the prevalent yeast 
host system, which is a good choice for production of therapeutic proteins that cannot be 
produced in functional forms by E. coli but do not stringently require human glycosylation 
patterns for the pharmacological activity. A variety of therapeutic proteins that are 
recombinantly produced by this system have been officially approved and commercialized, 
including human hirudin (Hoechst Marion Roussel, USA and Behringwerke AG, German), 
human glucagen (Novo Nordisk, Denmark), short-acting recombinant human insulin analog 
(Novo Nordisk), human platelet derived growth factor (Ortho-McNeil Pharmaceutical, USA 
and Janssen-Cilag, Switzerland), human growth factor (Biopartners, Switzerland), human 
papillomavirus recombinant vaccine (Merck, USA) and hepatitis B surface antigen (HbsAg), 
a component in combination vaccines Comvax (Merck), Tritanrix-HB (GSK) and 
Recombivax (Merck) [3]. 
At laboratory scale, the Pichia pastoris system, filamentous fungi systems (e.g., 
Aspergillus nidulans and Aspergillus niger), insect cell systems (e.g., Trichoplusia), 
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transgenic animals, and transgenic plants have been also under development, motivated by 
various advantages implicated in them [3, 16, 17].  
 
2.2 Recombinant Therapeutic Protein Production in E. coli 
2.2.1 Bioprocess Development 
E. coli still remains an important workhorse for recombinant therapeutic protein 
production, given the fact that 9 out of the 31 therapeutic proteins approved during 2003 and 
2006 are produced in E. coli [3]. A typical bioprocess for recombinant therapeutic protein 
production using an E. coli expression system consists of three technical stages, i.e. upstream 
for construction of the host/vector system, midstream for cultivation, and downstream for 
protein harvesting and purification (Figure 2.1). Protein production can be limited by gene 
expression, cultivation, or downstream processing. Corresponding strategies at all these 
levels are necessary to be established associated with molecular properties of therapeutic 
products. 
Genetic manipulation of the host/vector system can significantly enhance 
recombinant protein production in terms of mediating functional expression, increasing 
cultivation performance, and facilitating downstream purification. Genetic modification on 
the chromosome of the E. coli host is routinely carried out based on the complete sequence of 
the E. coli chromosome and versatile genetic techniques [18]. Since proteolysis by 
homologous proteases often occurs to recombinant proteins, genes encoding proteases are 
usually deleted. In this regard, E. coli B strain BL21 is a popular host as it retains good 
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growth characteristics while lacking both lon and ompT genes that encode proteases Lon and 
OmpT. Also, E. coli can be modified to grow more vigorously by eliminating key enzymes in 
the metabolic pathways that generates toxic metabolites (e.g., acetate), which is of peculiar 
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During the construction of expression vector, the use of a strong promoter system can 
increase the protein yield up to 10~30% or more of the total cellular protein [19]. Also, the 
use of a protein fusion tag not only facilitates protein purification but also enhances gene 
expression [20]. The targeting of recombinant protein needs to be determined and 
manipulated at this stage as well. Three compartments in E. coli are available (i. e. 
cytoplasm, periplasm and extracellular secretion) with well studied mechanisms and 
pathways [21, 22]. If targeting the protein to the cytoplasm, the cDNA sequence encoding the 
therapeutic protein lies downstream of the promoter. If targeting the protein to the periplasm, 
a proper signal sequence mediating the translocation across the inner membrane needs to be 
fused with the protein of interest. If targeting the protein to the extracellular secretion, in 
addition to the signal sequence, a carrier protein is frequently fused with target recombinant 
protein, for example, outer membrane protein F (OmpF) [23]. Otherwise, coexpression of 
genes encoding permeabilizing proteins (e.g., tolAIII, the gene encoding the third topological 
domain of the transmembrane protein TolA [24]) or physicochemical treatment to increase 
the permeability of the outer membrane needs to be performed. Alternatively, fusing the 
target protein directly to the C-terminal of hemlysin secretion signal sequence can 
straightforwardly secrete the product from the cytoplasm to the extracellular medium through 
the hemlysin transport system [25, 26]. The advantages and disadvantages of protein folding 
in these compartments will be discussed later. 
During cultivation in a bioreactor, the gene of interest is heterologously expressed in 
the exponential phase of cell growth upon induction. It is desirable to achieve both high-level 
gene expression and high cell-density culture. Corresponding strategies have been developed 
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on the basis of boosting cell growth, alleviating physiological deterioration, and enhancing 
functional gene expression. The medium recipe needs to be chosen by considering both the 
cost and the culture performance. In the case of extracellular production, less complex 
medium composition is preferred to simplify subsequent purification. The design of 
bioreactor and process control for E. coli cultivation has been well established with a long 
history [27]. Fedbatch cultivation is widely applied in industry to reach high cell-density 
culture [>100 g (dry cell weight)/L] but often limited by oxygen transfer and accumulation of 
growth-inhibiting metabolites. Cultivation parameters, such as pH, temperature, dissolved 
oxygen, and feeding profile, need to be monitored and adjusted to maximize culture 
performance. In addition, tradeoff between cell growth and functional gene expression needs 
to be carefully decided. For example, low temperature (e.g., 28 °C) is often chosen rather 
than high temperature (e.g., 37 °C) because insoluble expression often results at high 
temperature.  
Following cultivation, a series of separation steps are undertaken during downstream 
processing. Most of these steps require high volume solid-liquid separation and are usually 
performed by centrifugation or filtration. In the case of intracellular proteins, cells are 
harvested at the end of cultivation followed by several pretreatment steps, including cell 
lysis, removal of cell debris, and recovery of total protein, to obtain a concentrated crude 
protein extract. Cell lysis is typically achieved by homogenization in large-scale production. 
At laboratory-scale, chemical and enzymatic treatment is commonly employed. In the case of 
extracellular product, cell-free media are directly harvested and concentrated following 
cultivation. After concentration, a number of high-resolution chromatographic steps are 
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usually carried out under low, medium or high pressure, to achieve higher purity of 
therapeutic product. A range of chromatography systems are available to fulfill the 
purification task relying on the physiochemical interaction between the protein product and 
the chromatographic media, including gel-filtration, affinity, metal-chelate, ion-exchange, 
ceramic hydroxyapatite and hydrophobic interaction. Affinity chromatography is welcomed 
anywhere, particularly the first chromatographic step, as its high biospecificity facilitates to 
achieve a very high degree of purification in one-step operation. A number of protein affinity 
fusion tags with their corresponding chromatographic media have been developed [20]. 
Fusion tag cleavage can be conducted simultaneously with fusion protein binding to the 
chromatography media in order to facilitate separation of the target protein and fusion tag, an 
approach known as on-column cleavage [28]. A final polishing step is usually implemented 
to remove trace contaminant proteins. Therapeutic proteins produced in E. coli and other 
Gram-negative bacterial systems are easily contaminated by endotoxin (i.e. 
lipopolysaccharides on the outer membrane of bacteria), which is harmful for humans at 
dosage rates as low as 0.5 ng/kg body weight [10]. Colorimetric-based Limulus amoebocyte 
lysate (LAL) assay is commonly used to quantify the endotoxin in the final product in the 
unit of EU/mg (specific activity) or EU/mL (volumetric activity). Specific membrane 
products have been commercialized to remove endotoxin on the basis of charge reaction, for 
example, Mustang® E membrane from Pall Life Science. One more membrane 
chromatography step to remove endotoxin may be performed, if necessary. While solid bead-
packed columns are normally used as the media for chromatographic operation (i.e. column 
chromatography), the use of polymeric membranes (i.e. membrane chromatography) has 
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become popular, particularly in the polishing step (e.g., ion-exchange chromatography), due 
to much higher volumetric binding capacity and disposability [29].   
Finally, the purified therapeutic product is formulated for storage. The final 
formulation has significant impacts on product quality of therapeutic proteins. Huge efforts 
have been made in this process, especially in the pharmaceutical industry. The basic goal of 
formulation is to maintain or enhance the stability and efficacy of the protein product during 
storage, transportation and administration. Its success depends on the understanding of the 
physicochemical factors of protein instability and the thermodynamic mechanism for protein-
solvent interaction [30]. There are certain general principles to follow. Extremely high or low 
temperature will accelerate protein unfolding or other structure destructions. Proteins 
ubiquitously exhibit extraordinary pH dependence because charged groups play an important 
role in determining the structure and function of the protein in solution. Agitation and shear 
can disrupt protein structure to some extent and become more severe upon exposure of the 
protein to hydrophobic interfaces [31, 32]. A solid formulation of a biopharmaceutical is 
preferred sometimes to liquid formulation in order to avoid chemical degradations in 
solutions. Lyophilization (freeze-drying) is the most common method to achieve this 
purpose. Also, a wide variety of excipients have been often added during the formulation, 
either liquid or solid form, to stabilize therapeutic proteins [33].  
2.2.2 Technical Issues and Approaches 
While progress is continuously being made in recombinant therapeutic protein production, 
certain technical issues pertinent to assuring consistent quality of therapeutic products are 
still challenging. Protein molecules are marginally stable, and thus their structure is easily 
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partially or completely altered due to various physicochemical stresses during downstream 
processing and subsequent storage and transportation. Destabilizing mechanisms have been 
reviewed in detail and employed as the general guidelines for the formulation of therapeutic 
protein products [31, 34]. A summary overview is provided below.  
The side-chain amide groups of asparagine and glutamine amino acids are peculiarly 
susceptible to hydrolysis which yields aspartic acid or glutamic acid, respectively. This 
reaction is known as deamidation, a major mechanism by which insulin products degrade. 
Imide formation frequently occurs to asparagine, aspartic acid, glutamine or glutamic acid 
reacting in aspartimides or glutarimides. Imide formation is promoted by X-Gly, X-Ser and 
X-Ala sequences (X represents asparagine, aspartic acid, glutamine or glutamic acid), 
resulting in increased vulnerability to hydrolysis. The studies conducted on a case-to-case 
basis reveal that deamidated proteins usually exhibit shortened half-life, because they 
become more susceptible to proteolysis. The protein conformation can be partially changed 
owing to increased net negative charge on the surface. Consequently, disassociation or 
unfolding might occur. Refolding can be inhibited by deamidation due to the increased 
repulsion, which might lead to aggregation of unfolded proteins. 
Several amino acids are very sensitive to oxidative stress. Methionine can be oxidized 
to give methionine sulfoxide and even methionine sulfone. The most prominent reaction 
products of tryptophan oxidation are N’-formylkynurenine and 3-hydroxykynurenine. 
Tyrosine may be oxidized to dityrosine which can lead to covalently linked dimer. Histidine 
can be changed to 2-oxo-imidazoline through metal–catalyzed oxidation. Oxidation of 
cysteine can result in disulfide bond as well as sulfenic acid, sulfinic acid and sulfonic acid. 
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Although conformational changes do not always occur except when there are modifications 
of the disulfide bond, altered pharmaceutical behaviors are observed due to oxidation, 
including loss in bioactivity, reduced half-lives, as well as changed pharmacokinetics and 
immunogenicity.  
In the end, inconsistent biological activity may result. While formulation stabilizes 
final products during extensive storage, corresponding bioprocessing strategies are necessary 
to improve the performance of therapeutic protein production. Modifications on protein 
primary structure are frequently conducted to help attain structure consistency. A number of 
molecular manipulation techniques can be adopted, including site-directed mutagenesis, 
directed evolution mutagenesis, and error-prone PCR. Since proteins undergo various 
environmental stresses during downstream processing, shortened operation time and mild 
operation conditions (e.g., avoiding high temperature and extreme pH) should be managed as 
much as possible. Due to the diversity and speciality of structure and function of protein 
molecules, establishment of effective approaches entails identification of critical factors 
leading to inconsistent conformation and biological activity on a case-by-case basis.  
2.2.3 Structural Analysis of Final Product 
1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is the most commonly used technique in the assessment of final product purity. 
It separates proteins based on their different mobility in an SDS gel, which is primarily 
determined by the molecular weight of protein. Bands containing as little as 100 ng proteins 
can be visualized by staining the gel with dyes such as Coomassie blue. The detection 
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sensitivity can be even increased up to 100-fold with the use of silver nitrate staining. The 
bands additional to those associated with the protein product generally correspond to protein 
impurities. Quantification of purity can be conducted on the basis of densitometry.   
SDS-PAGE is usually run under reducing conditions. Supplement of a reducing 
agent, such as β-mercaptoethanol or dithiothreitol, is conducted during SDS sample 
preparation to break down the intra- and intermolecular disulfide bonds. It can be run under 
non-reducing conditions where disulfide bonds are retained so that more information on 
protein structure can be obtained. Multimerization formed via intermolecular disulfide bonds 
can be characterized. Also, the presence of intramolecular disulfide bond(s) can be detected 
since the mobility of protein with intramolecular disulfide bond is greater than that with free 
sulfhydryl groups [35]. 
With the development of electrophoresis apparatus, two-dimensional (2-D) 
electrophoresis can be conveniently conducted to analyze the purity and structure 
homogeneity of final product. The mostly utilized method entails separation of proteins by 
isoelectric focusing (IEF) in the first dimension, with separation in the second dimension 
being undertaken in the presence of SDS.  
2. High Performance Liquid Chromatography (HPLC) 
Chromatography systems are widely applied in analyzing the purity and structure of protein 
product and usually operated under high pressure, such as size-exclusion (SEC) and 
reversed-phase (rp-HPLC). Sophisticated models of HPLC systems with automatic sampling 
and band analyzing are commercially available, equipped with on-line UV detectors set at 
~220 or ~280 nm wavelengths. The stationary phase in the SEC is cross-linked agarose of 
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defined pore size supported by silica.  It separates proteins primarily based on the size and is 
frequently utilized to analyze multimers or aggregates, as well as proteolyzed or hydrolyzed 
degradation products. rp-HPLC is a very sensitive analytical technique. It is capable of 
separating proteins of nearly identical structure but with minor differences in their surface 
hydrophobicity. The stationary phase in the rp-HPLC column normally consists of silica or 
polymeric support material to which hydrophobic alkyl chains are chemically attached. Three 
types of rp-HPLC columns, C4 (butyl group), C8 (octyl group), and C18 (octadecyl group), 
are correspondingly suitable in separation of proteins or peptides from high to low molecular 
weights. Mobile phase are commonly organic solvents, such as acetonitrile, trifluoroacetic 
acid and methanol. Proteins entering the column adsorb to the hydrophobic surface and 
remain adsorbed until the organic solvent concentration reaches a specific concentration 
(known as elution gradient), when the protein desorbs from the surface. Hence, the elution 
gradient represents the surface hydrophobicity of proteins.  
3. Mass spectrometry 
With the advent of desorption/ionization techniques, it is possible to analyze large 
biomolecules using mass spectrometry (MS), such as fast atom bombardment (FAB), 
electrospray (ESI), and matrix-assisted laser desorption ionization (MALDI) MS analysis, 
which provides a rapid and sensitive approach to characterize protein structural alterations  as 
well as plays a pivotal role in peptide mapping.  
4. Circular Dichroism (CD) 
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The chiral nature of peptide bond gives rise to CD signal when circularly polarized light 
beams pass through proteins. The protein secondary structure can be accurately characterized 
by far-UV CD measurement (180~250 nm) because peptide bonds are the dominant 
chromophores in this region. The tertiary structure can be reflected by the spectra obtained in 
the near-UV region (250~300 nm), in which aromatic amino acids and disulfide bond 
contribute to the CD signal to some extent. In addition to identification of banding features of 
each secondary structure (i.e. α-helix, β-sheet, and unordered structure) in spectra, fractional 
contents of each type can be deconvoluted by a number of programs which are accessible on 
line, e.g., DichroWeb, (http://dichroweb.cryst.bbk.ac.uk/html/process.shtml). CD 
measurement is conducted on a spectropolarimeter equipped with CD detector and widely 
applied in thermal stability characterization and ligand binding of protein.  
5. Fluorescence Spectroscopy 
Amino acids, like tryptophan, tyrosine and phenylalanine, give rise to fluorescence signals at 
the excitation wavelengths ranging from 280 to 300 nm. Among them, the emission 
fluorescence from the tryptophan residue is most sensitive to structural changes and thereby 
most often employed to monitor the local tertiary structural changes. Accordingly, longer 
excitation wavelengths (> 295 nm) that specifically energize tryptophan residue are chosen. 
Fluorescence is measured using a spectrofluorometer at a designated excitation wavelength 
with emission spectra being recorded. The emission maximum wavelength and 




2.3 Folding and Misfolding of Recombinant Protein in E. coli 
E. coli has naturally developed mechanisms to help fold homologous proteins that suffer 
from misfolding. These mechanisms can also be used to assist the correct folding of 
heterologous proteins expressed in this system. E. coli has two sets of folding modulators, 
including molecular chaperones that prevent aggregation and misfolding by shielding the 
proteins in their cavity, and folding catalysts that accelerate rate-limiting steps during protein 
folding, such as the isomerization of peptidyl-prolyl bonds from an abnormal cis to a trans 
conformation.  
2.3.1 Folding of Recombinant Protein in Cytoplasm  
Upon being released from the ribosome, the newly synthesized polypeptides instantaneously 
enter the de novo folding pathways in the cytoplasm mediated by a number of chaperones. 
First, the short chain proteins primarily interact with trigger factor (TF), which moderately 
binds the ribosome at a location close to the peptide exit site. TF displays peptidyl-prolyl 
cis/trans isomerase activity (PPIase), which is the only PPIase identified in the cytoplasm. 
The longer chain proteins preferably bind to chaperone DnaK and subsequently are processed 
by the DnaK-DnaJ-GrpE system. Following undocking from two systems, a nascent protein 
may reach a native conformation, cycle back to the two systems until it folds, or flow to the 
downstream GroEL-GroES system which constructs a chamber in the center for proteins to 
undergo conformational changes at infinite dilution. E. coli has also evolved mechanisms to 
refold proteins which fold improper because of environmental stress. Partially folded or 
misfolded proteins are stabilized by holding chaperones, such as IbpA, IbpB, Hsp31 and 
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Hsp33, while awaiting DnaK and GroEL to refold them to correct conformation. In the case 
of formation of large and insoluble aggregates, E. coli has developed a mechanism to 
solubilize them which is primarily mediated by a disaggregating chaperone ClpB. 
Renaturation of solubilized aggregates is specifically performed by DnaK-DnaJ system. 
Misfolding and inclusion body formation remain serious issues for cytoplasmic 
expression. This situation can be attributed to the overexpression of recombinant proteins 
which is mediated by strong promoters and high inducer concentrations. The folding 
modulators are rapidly used up, thereby leaving certain amount of protein misfolded.  In 
addition, E. coli lacks the cytoplasmic machinery to perform all post-translational 
modifications that may be critically required for correct protein folding.  
2.3.2 Export and Folding of Recombinant Protein in Periplasm 
While some proteins remain in the cytoplasm, proteins with amino-terminal signal sequences 
are destined for export to the periplasm. There are three mechanisms for translocation across 
the inner membrane. The Sec-dependent pathway is responsible for secreting most proteins, 
which is composed of SecB, SecA, SecYEG, and SecYajC complex. SecB, a cytoplasmic 
secretory chaperone, possessing two 70-Å-long hydrophobic channels along its sides, is 
generally adopted to maintain preproteins in an extended form. Subsequently via its acidic 
top region, SecB docks and transfers the preprotein to the peripheral membrane protein 
SecA. Driven by ATP-hydrolysis, SecA and the cargo preprotein are transported to the pores 
formed by the integral membrane protein SecYEG.  
Assisted by the SecDFYajC complex, the translocation to the periplasm is attained. During 
this process, the signal peptide is cleaved by the membrane-associated Lep or Lsp signal 
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peptidases. The second export pathway is the signal recognition particle (SRP)-dependent 
pathway which specifically translocates preproteins with highly hydrophobic signal 
sequences and transmembrane segments of inner membrane proteins. While both Sec- and 
SRP-dependent pathways are usually engaged in secreting unfolded preproteins, the twin-
arginine (Tat)-dependent pathway exclusively exports folded or partially folded preproteins. 
Proteins translocated via the Tat-dependent pathway are frequently fused with a signal 
sequence containing a twin arginine motif.  
After being translocated, mature proteins (after signal sequences are cleaved) are 
subject to folding in the periplasm assisted by a variety of periplasmic folding modulators. 
Skp primarily captures outer membrane proteins and misfolded periplasmic proteins. A group 
of modulators function as PPIases with rather broad substrate spectra, such as SurA, PpiD, 
FkpA, and PpiA. There are a number of modulators interacting with specific substrates to 
carry out chaperone activity, including SurA, LolA, PapD, and FimC.  The coexpression of 
these modulators has been frequently employed to improve the extracytoplasmic expression. 
In the meantime, cell physiology was observed to be significantly enhanced by 
overexpression of Skp and FkpA during surface display, presumably due to alleviated stress 
response [36, 37]. 
One of the most distinguishable features of the periplasm is its oxidizing environment 
which enables disulfide bond formation. A set of sulfhydryl-disulfide oxidoreductase known 
as Dsb proteins have evolved to catalyze disulfide bond formation and isomerization in 
newly translocated proteins. Most periplasmic Dsb proteins contain a catalytic CXXC motif. 
This motif is kept in either reduced form (Dsb-(SH)2) or oxidized form (Dsb-S2), depending 
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on their primary function. While the DsbA and DsbB are engaged in the oxidation of cysteine 
residues, DsbC and DsbD mediate the isomerization of disulfide bond. The oxidative form of 
DsbA is a powerful oxidant and quickly reacts with unfolded proteins as they enter the 
periplasm, membrane-bound DsbB functions to maintain the oxidative form of DsbA. DsbA 
is not a specific oxidant and can introduce nonnative disulfide bonds into protein. These 
incorrect disulfide bonds need to be corrected to avoid misfolding and aggregation. This task 
is fulfilled by isomerization process. The DsbC is maintained in a reduced form by the inner 
membrane DsbD at the expense of NADPH oxidation in the cytoplasm. Recently, a new 
family member DsbG was identified that functions similar to DsbC. The overexpression of 
Dsb proteins, particularly DsbC has been used to improve the correct disulfide bond 
formation during the production of recombinant therapeutic proteins [11]. 
In the meantime, the periplasm also develops proteolysis mechanism to discard 
misfolded proteins, although the level of proteases is much lower than that of the cytoplasm. 
DegP and Prc are the most well studied periplasmic proteases together with several other 
proteases, including DegS, DegQ, and Protease III.  
2.3.3 Extracellular Secretion of Recombinant Protein 
Secretion to the extracellular medium may be the most ideal way to produce recombinant 
proteins. It does not only simplify the downstream processing, but also promotes soluble and 
bioactive expression of the target therapeutic proteins, in particular their disulfide bond 
formation in the periplasm as well as outside the cell. E. coli have evolved mechanisms for 
secretion to discard detrimental proteins [22]. The Sec-dependent system is the most widely 
used secretion pathway which relies on the Sec system for translocation across the inner 
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membrane and both the characteristics of signal sequence and proteins for extracellular 
secretion. There is no universal principle in selecting a proper signal sequence for a given 
recombinant protein to guarantee its successful secretion. Several commonly used signal 
peptides, either homologous or heterologous, need to be examined by trial and error. A 
detailed list of these signal peptides and their applications are summarized by Choi [21]. To 
improve the secretion efficiency of this system, it is essential to manipulate the folding of 
recombinant protein in the periplasm, such as co-expression of periplasmic folding 
modulators and minimizing periplasmic proteolysis. In the meantime, its extracellular 
secretion efficiency can be enhanced by fusing the target protein to a carrier protein, either 
normally secreted or integrated into the outer membrane. In addition, increasing the 
permeability of the outer membrane can help efficient excretion. Both chemical and genetic 
strategies have been developed for this purpose. Supplement of glycine and Triton X-100 to 
the medium and physicochemical treatment of cell membrane (e.g., osmotic shock, 
freezing/thawing, chloroform) are frequently used to create “leaks” in the outer membrane. 
Also, co-expression of kil [38], TolAIII [24], out [39], or bacteriocin release protein (BRP) 
genes can augment the yield of extracellular production [40].  
The hemolysin transporter system (Hly) is another popular secretion system [21]. The 
complex formed by inner membrane protein HlyD trimer and HlyB interacts with the outer 
membrane protein TolC to form an export conduit to transport the HlyA toxin/HlyA-fusion 
protein from the cytoplasm to the extracellular medium. By fusing to the C-terminal of Hly 
secretion signals, a number of therapeutic proteins have been successfully secreted in an 
active form, including single chain Fv antibody [25] and human interleukin-6 [26].  
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2.4 Disulfide Bond in Proteins 
Proteins are linear polypeptide chains that fold into a 3-D structure to yield a functioning 
molecule. The principles governing protein folding have been postulated by Christian 
Anfinsen, who received the Nobel prize for this work. He postulated that all the information 
required for the proper folding of a protein to its native 3-D structure is contained in its 
amino acid sequence [41]. The 20 constituent amino acids mainly interact via electrostatic, 
Van der Waal, hydrogen bonding, and hydrophobic forces. Cysteine is the only amino acid 
that allows the formation of covalent bonds. This bond is known as a disulfide bridge and is 
formed via the cross-linking of two sulfhydryl groups in two cysteine residues through 
oxidization. Disulfide bridges are present in numerous proteins across a wide variety of 
organisms ranging from simple unicellular prokaryotes to complex multi-cellular organisms.  
2.4.1 Effects on Protein Stability  
Owing to its covalent nature, disulfide bonds are generally believed to stabilize proteins, 
especially under extremely harsh conditions. Bovine pancreatic ribonuclease A [42] is a 
classical example of protein stabilization through disulfide bonds. Efforts have been made to 
improve protein stability via de novo engineering of disulfide bonds. However, successful 
cases are very limited mainly due to the fact that the mechanism by which the disulfide bond 
stabilizes protein remains imprecise [43]. By far, the stabilizing effects of disulfide bonds are 
proposed to be a result of reduction in conformational entropy in the unfolded state [44], 
combinatory entropic and enthalpic effects that involve not only interactions within protein 
chains but also interactions with surrounding solvents [45], or primarily enthalpic effects 
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[46]. In any case, it is a well established fact that the protein with native (or correct) disulfide 
bonds are more stable than variants without disulfide bonds [45]. Furthermore, the pattern (or 
position) of disulfide bonds is believed to significantly affect the stability of the protein. 
While correct disulfide bonds stabilize proteins, incorrect disulfide bonds may result in a 
destabilizing effect. In many cases, the formation of correct disulfide bond in proteins is 
essential for them to reach or stabilize a biologically active conformation. For example, 
human insulin requires correct formation of intra- and interchain disulfide bonds to function 
properly. The inability to form disulfide bond and/or aberrant disulfide bond formation is the 
key factor leading to the protein misfolding, e.g., inclusion body formation in E. coli.  
2.4.2 Disulfide Bond Chemistry 
The in vivo formation of disulfide bonds is carried out during post-translational processing 
and is assisted by a series of oxidoreductases in prokaryotes [47] or protein disulfide bond 
isomerases (PDI) in eukaryotes [48]. There are three kinds of reactions involved, including 
oxidation, reduction, and isomerization (Figure 2.2).  
By reacting with the oxidase, a disulfide bond is introduced to the substrate protein. 
Equivalently, a disulfide bond formed in the substrate protein can be reduced by the 
reductase. The rearrangement of disulfide bonds within a substrate protein can occur through 
two different mechanisms: a two-step process with a reduction reaction followed by an 
oxidation reaction or a single-step isomerization process. The two-step mechanism involves 
the presence of two oxidoreductases, an isomerase that reduces the disulfide bond and an 
oxidase that forms the disulfide bond. On the other hand, the single step mechanism involves 
only the isomerase enzyme. In this case, the assisting oxidoreductase forms a mixed disulfide 
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by attacking an existing disulfide bond. Depending on the conformation, such mixed 
disulfide bond may be resolved by an adjacent cysteine residue resulting in the formation of a 


















Figure 2.2 The in vivo disulfide bond reactions catalyzed by oxidoreductases. (A) Oxidation, 




































All the above reactions can take place in vitro as well, for example, during 
downstream processing and/or storage. Atmospheric oxygen and small sulfhydryl-disulfide 
chemical reagents such as glutathione and DTT are usually employed to function in a similar 
way as the oxidoreductases. The rearrangement of disulfide bonds within the protein may 
even occur in the absence of an exogenous sulfhydryl-disulfide reagent. The protein 
sulfhydryl groups may attack the existing disulfide bond, resulting in sulfhydryl-disulfide 
exchange. This is known as disulfide scrambling that can take place intra- and 
intermolecularly, potentially leading to protein conformational changes (Figure 2.3). It is 
particularly aggravated under protein destabilizing conditions, e.g., in the presence of 
denaturant or high temperature. Disulfide bonds may also undergo irreversible β-elimination 
reactions in alkaline solutions as shown in Eq. a and b: 
 
       R1CH2SSCH2R2 + OH-  R1CH2SS- + CH2 == CR2 + H2O      (a) 
                 R1CH2SS- + OH-  R1CH2SO- + HS-                               (b) 
 
Hydroxides attack protein disulfide bond, and as a result, disulfide bonds are cleaved 
concomitant with the formation of dehydroalanine and persulfide. Following an electrophilic 
addition reaction, ε-amino group of lysine or the sulfhydryl of cysteine can be inserted to the 
double bond of dehydroalanine, yielding lysinoalanyl or lanthionyl cross-links, respectively. 
Persulfides may further react with hydroxide to release hydrosulfides that open chances to 
introduce additional modifications to the protein, such as disulfide scrambling [49]. The β-
elimination develops very rapidly at 90~ 100 °C in the pH range of 6 to 8 or at room 
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temperature in extremely basic solutions. Hence, β-elimination is recognized as a major 
protein degradation mechanism. 
2.4.3 Disulfide Bond in Protein Folding 
In many cases, proteins do not fold to their native conformation until nearly all of its native 
disulfide bonds have been formed, suggesting that disulfide bond can be a probe to 
investigate protein folding pathways [50, 51]. Bovine pancreatic trypsin inhibitor (BPTI) has 
long been a model protein to study the mutual effects of disulfide bond formation and 
conformational folding on each other [50, 52, 53]. Oxidative folding processes of fully 
reduced and denatured proteins are usually initiated by introducing sulfhydryl-disulfide 
reagents. Mixed disulfide bonds are then formed between protein molecules and reagents. 
Followed by numerous sulfhydryl-disulfide exchange reactions, substantial disulfide bonded 
folding intermediates are captured and characterized to elucidate disulfide-coupled folding 
pathways. Similar methodology has been successfully applied to decipher the folding 
pathways of a number of proteins, including porcine insulin [54], human proinsulin [55], and 
RNase A [56]. Great detail on folding pathways only can be obtained if the disulfide bonded 
intermediates are stable and can accumulate to significant level. Disulfide bond patterns in 
the intermediates are usually explored by peptide mapping relying on chemical/enzymatic 





















Figure 2.3 Disulfide scrambling. (A) sulfhydryl-disulfide exchange reaction occurs 
intramolecularly, resulting in a different intramolecular disulfide bond.  (B) sulfhydryl-
disulfide exchange reaction occurs intermolecularly, resulting in formation of an 
intermolecular disulfide bond, (C) An intermolecular disulfide bond is broken by a sulfhydryl 


































2.5 Disulfide Bond Formation in Recombinant Therapeutic Protein 
Production 
Many commercialized therapeutic proteins contain disulfide bonds. The correct formation of 
disulfide bonds is often a prerequisite for these proteins to achieve their biologically active 
three-dimensional (3D) conformation [56-58]. On the other hand, aberrant formation of 
disulfide bonds has been recognized as a critical factor leading to protein misfolding, 
aggregation, and malfunction [59-62]. Therefore, the production of bioactive therapeutic 
proteins can be limited by the correct formation of disulfide bonds. This technical issue is 
particularly more challenging when E. coli is used as the expression system since it lacks the 
cellular machinery as efficient as that of the mammalian expression system to regulate this 
posttranslational event. Subsequent exposure of the protein intermediate or final product to 
an oxidative environment during downstream processing and storage stages can also result in 
the aberrant formation of  disulfide bonds and/or the interchange between free sulfhydryl 
groups and disulfide bonds, known as disulfide scrambling [51, 56].  
Rearrangement of disulfide bond, known as disulfide shuffling, can be performed in 
vitro to achieve a desirable disulfide bond pattern. It starts with denaturing and reducing 
protein polypeptides followed by exposing polypeptides to redox reagents, such as 
glutathione, dithiothreitol and cysteine. Theoretically, disulfide bonds are first formed 
between polypeptides and redox reagents. Subsequently, free cysteine residues in the 
polypeptides will be involved in sulfhydryl/disulfide exchange reactions to form desirable 
intramolecular disulfide bonds. The redox state of the protein solution can be precisely 
controlled by the concentrations of the reduced and oxidized forms of the redox reagent as 
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well as their ratio to the polypeptide-cysteine concentration. Using this approach, several 
disulfide-bond-containing therapeutic proteins, including human interleukin-4 (with three 
disulfide bonds) [63] and tissue plasminogen activator (t-PA; with 17 disulfide bonds) [64], 
have been successfully renatured to achieve their correct disulfide bond patterns. Likewise, 
the inclusion of redox reagents in downstream processing steps is anticipated to be helpful 
[65]. Protein disulfide isomerases (PDIs) from different sources have been exploited, either 
in a free or an immobilized form [66], to promote the correct formation of disulfide bonds in 
vitro [67, 68], particularly in cell-free systems for protein synthesis [69].  
From a technical point of view, it is still desirable to express proteins with a correct 
disulfide bond pattern in E. coli since no extra processing will be required for disulfide 
shuffling and protein refolding. In addition, the intracellular environment is supposed to be 
more consistent than the in vitro one for disulfide bond formation. The periplasm of E. coli is 
an ideal intracellular compartment to express proteins with disulfide bonds because it is 
oxidative and possesses the Dsb-family proteins for mediating the in vivo formation disulfide 
bonds [47]. The overexpression of the Dsb-family proteins appears to significantly facilitate 
the formation of disulfide bonds for the functional expression of several therapeutic proteins, 
such as leptin, single-chain Fv antibody fragment, and t-PA [70-72]. Nevertheless, 
heterologous protein expression targeting this compartment is often limited by ineffective 
translocation. As a result, E. coli expression systems enabling the formation of disulfide 
bonds in the cytoplasm have been developed [73-75] and several strains, e.g. Origami 
(Novagen; with two deletions of the trxB gene encoding thioredoxin reductase and the gor 
gene encoding glutathione reductase) and SHuffle (New England Biolab; similar to Origami 
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but with an overexpression of DsbC), have been made commercially available. The approach 
of cytoplasmic expression has been explored for the functional expression of several 
proteins, including Fab antibody fragment [76], t-PA [73], lipase B [77], and human 11-β-
hydrooxysteroid dehydrogenase [78].  
Since disulfide bonds are formed by crosslinking cysteine pairs transiently close to 
each other, it is plausible to assume that the formation probability can be explicitly 
determined by protein structure or even intrinsically encoded by protein sequence. However, 
up to now, there is limited knowledge and experimental demonstration as to how protein 
conformation and/or protein sequence can affect the formation mechanism associated with 
aberrant disulfide bonds. Theoretically, to ensure consistent quality of therapeutic products, 
protein molecules should be designed and produced in such a way to both mediate a fixed 
disulfide pattern and to prevent the formation of aberrant disulfide bonds. In this regard, 
understanding various structural factors associated with disulfide bond formation becomes 
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3.1 Introduction 
In this work, we developed a bioprocess for effective production of hCD83ext with a high 
quality suitable for various in vivo and in vitro trials for bioactivity evaluation. Culture 
conditions were determined based on maximization of the volumetric recombinant protein 
titer by manipulating various operating parameters, including medium recipe, host/vector 
system, induction condition (e.g. inducer concentration and induction timing), temperature, 
and dissolved oxygen. Downstream processing steps were established based on several 
 
  35
purification criteria, such as product throughput, yield, purity, and endotoxin level. In 
addition, extensive monitoring of the structural change, multimerization, and stability 
associated with the final hCD83ext product was conducted. 
 
3.2 Materials and Methods 
3.2.1 Bacterial Strains and Plasmids 
The plasmid of pGEX2ThCD83ext containing the hCD83ext cDNA fused with the gst gene 
was used as the expression vector for the production of recombinant GST-hCD83ext under 
the regulation of an isopropyl β-D-thiogalactopyranoside (IPTG)-inducible tac promoter [8]. 
Due to the design of a thrombin cleavage site at the junction between GST and hCD83ext, 
the final hCD83ext product has four extra AAs, i.e. Gly-Ser-Pro-Gly, in the amino terminus 
and this modification was presumed to have no effect on the property of hCD83ext. BL21 (F¯ 
ompT gal [dcm] [lon] hsdSB (rB¯ mB¯)) [79] was used as the expression host. Purification of 
plasmid DNA was performed using a spin-column kit (BD Biosciences Clontech, 
Mississauga, Ontario, Canada). Plasmid transformation was carried out using a chemical 
method. Cultivation cells were revived by streaking the stock culture, stored at -80 °C, on LB 
agar plates (5 g/L NaCl, 5 g/L Bacto yeast extract, 10 g/L Bacto tryptone, and 15 g/L Bacto 
agar). The plate was incubated at 37 °C for approximately 15 h. An isolated single colony 
was picked to inoculate 100 mL of LB medium, which was then incubated at 37 °C on a 
rotary shaker at 200 rpm for approximately 12 h. The medium was supplemented with 50 
μg/mL ampicillin (Ap) when necessary. The seed culture (80 mL) was used to inoculate a 
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bench-top bioreactor (Omni-Culture, VirTis, Gardiner, NY, USA) containing 1-L working 
volume of culture medium (5 g/L NaCl, 20 g/L Bacto yeast extract, 20 g/L Bacto tryptone, 5 
g/L glucose, and 10 μL/L Antifoam 289 (Sigma, St. Louis, MO, USA)). When the culture 
cell density reached ~2 OD600, IPTG at 0.5 mM was added for induction. The bioreactor was 
purged with filter-sterilized air at 2 L/min for aeration. The culture pH was regulated at 7.0 ± 
0.1 by adding 3 N NH4OH or 3 N HCl using a combination of pH electrode (Mettler-Toledo, 
Switzerland), a pH controller (PC310, Suntex, Taipei, Taiwan), and two peristaltic pumps 
(101 U/R, Watson Marlow, Falmouth, UK). The bioreactor was operated at 28 °C and 650 
rpm for approximately 6 h after induction. 
3.2.2 Sample Treatment for Analyses 
The culture sample was appropriately diluted with saline solution for measuring cell density 
in OD600 with a spectrophotometer (DU® 520, Beckman Coulter, Fullerton, CA, USA). For 
the preparation of cell extract, cells in the amount of 30 OD600-units (defined as ‘OD600 × 
mL’) were centrifuged at 6000 × g and 2 °C for 10 min. The cell pellet was resuspended in 
0.75 mL phosphate-buffered saline (pH 7.3), sonicated intermittently (i.e. 0.5 s/0.5 s on/off) 
for 4 min using an ultrasonic processor (Misonix, Farmingdale, NY, USA) with a microtip, 
and then centrifuged at 15,000 × g and 2 °C for 15 min to remove cell debris. The 
supernatant containing soluble proteins was used for various analyses, including GST assay, 
SDS–PAGE, and Western blotting. The pellet containing insoluble proteins and cell debris 
was washed with phosphate buffer, resuspended in TE/SDS buffer (10 mM Tris–HCl, pH 
8.0, 1 mM EDTA, 1% SDS), and heated to 100 °C for 5 min for dissolution. The protein 
content of the pellet was analyzed as the insoluble fraction. 
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3.2.3 Downstream Processing 
After cultivation, the cells were harvested as described above, weighed, and stored at -80 °C 
for later processing. Typically, cell paste at approximately 20 g wet cell weight (wcw) could 
be obtained from 1-L culture. Cell suspension at 0.05 g wcw/mL was prepared by suspending 
the cell paste in PBS. A batch of 20-mL cell suspension at approximately 20 OD600 was 
sonicated intermittently (i.e. 0.5 s/0.5 s on/off) for 4 min using an ultrasonic processor with a 
regular tip (XL-2020; Misonix, Farmingdale, NY, USA). The processed cell lysate was then 
centrifuged at 15,000 × g and 2 °C for 15 min to remove cell debris. The supernatant 
containing total soluble proteins was filtered with a 0.45 μm filter before subsequent 
chromatographic processing for protein purification.  
To capture the GST-hCD83ext fusion, the above-prepared lysate with PBS as a 
binding buffer was loaded into a GST affinity chromatographic column (GE Healthcare, Baie 
d’Urfé, Québec, Canada). The bound GST-hCD83ext fusion was in-situ cleaved with 
thrombin (Sigma). To conduct on-column cleavage, the binding buffer in the GST affinity 
chromatographic column bound with GST-hCD83ext fusion was replaced by the same 
volume of the binding buffer containing thrombin at a designated concentration through 
manual injection. The cleavage was conducted at room temperature for approximately 2.5 h 
and the bulk liquid in the GST affinity chromatographic column was ejected using 1 column 
volume of the binding buffer. The GST moiety along with undigested GST-hCD83ext was 
then eluted using the elution buffer (50 mM Tris, 10 mM glutathione, pH 8.0).  
The polishing step was conducted to remove thrombin and other contaminant proteins 
from hCD83ext. A low-pressure chromatographic system (BioLogic LP, BioRad, Hercules, 
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CA, USA) equipped with a strong anion exchange column (Q, GE Healthcare) was used for 
the processing. Tris buffer (20 mM, pH 7.5) with 50 mM NaCl and Tris buffer with 1 M 
NaCl were used as the loading and elution buffers, respectively.  
The fractions containing the pure hCD83ext were pooled and concentrated with 
ultrafiltration using a high-pressurized stirred cell (Amicon, Model 8010 with YM10 disk, 
Millipore Canada, Cambridge, Ontario, Canada). The hCD83ext final product was filter-
sterilized before storage. Using this final product fraction, the extinction coefficient of 
hCD83ext was determined to be approximately 1.16 OD280-mL/mg/cm.   
3.2.4 Analytical Methods 
GST was assayed at ambient temperature using 1-chloro-2,4 dinitrobenzene (CDNB) and 
glutathione as the substrates. GST (or its fusion) catalyzes the reaction of the two substrates 
to form a conjugate product that can be monitored at 340 nm. One unit (UGST) is defined as 
the amount of enzyme that causes an increase in absorbance at 1 OD340/min. The volumetric 
activity (in UGST/mL) is the product of the specific activity (in UGST/OD600-unit) and cell 
density (in OD600). Total proteins were assayed using a bicinchoninic acid kit (Sigma-
Aldrich, St. Louis, MO, USA). LAL assay was conducted to measure the endotoxin level 
using a commercial kit  from Cambrex (East Rutherford, NJ, USA).  
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was 
performed in a Mini-PROTEAN® II electrophoresis cell (Bio-Rad, Hercules, CA, USA) 
using a 12.5% polyacrylamide separating gel stacked by a 4% polyacrylamide stacking gel. 
Electrophoresis was conducted at a constant voltage of 120 V for approximately 2 h. The gel 
was stained with Coomassie blue or silver nitrate and dried. The dried gel was scanned.  
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To conduct Western blotting, the proteins on the polyacrylamide gel were 
electroblotted to a poly(vinylidene difluoride) (PVDF) membrane (Pall Life Sciences, 
Pensacola, FL, USA) after SDS–PAGE using a Mini Trans-Blot® Cell (Bio-Rad) according 
to a standard protocol [80]. The electrophoretic transfer was conducted at a constant voltage 
of 100 V for 1 h. Protein–antibody binding was performed as described by Sambrook et al. 
[81]. Mouse monoclonal anti-CD83 antibody (CD83-1G11, Cedarlane laboratories limited, 
Hornby, Ontario, Canada) was used as the primary antibody. On the other hand, the purified 
hCD83ext was used as an antigen for raising polyclonal anti-CD83 antibodies in rabbits. It 
appears that the two types of antibodies have the same binding affinity to various hCD83 
species (data not shown). The secondary antibody was goat anti-mouse IgG conjugated with 
horseradish peroxidase (Sigma-Aldrich). hCD83-related polypeptides (e.g. GST-hCD83ext 
and hCD83ext) were detected by a colorimetric method using 3,3'-diaminobenzidine 
tetrahydrochloride (DAB) as the substrate. The processed membrane was scanned.  
Far-UV circular dichroism (CD) spectra of protein samples were obtained using a 
spectropolarimeter (Jasco-815; Jasco, Tokyo, Japan). Fluorescence emission spectra (over the 
range of 300~420 nm) of protein samples were obtained using a spectrofluorometer (FP-
6500; Jasco) with an excitation wavelength at 295 nm. All the spectroscopic measurements 





Using a bench-top bioreactor for cultivation for the production of recombinant GST-
hCD83ext, several culture parameters, including medium recipe, induction condition (i.e. 
induction timing and IPTG concentration), agitation speed, and temperature, were found to 
critically affect the culture performance. The cultivation was terminated at approximately 6 h 
after induction since the protein yield reached a plateau and would decrease upon extended 
cultivation. The downstream processing primarily consists of three stages for hCD83ext 
purification. Initially, the expressed GST-hCD83ext was captured in a GST-affinity column. 
Subsequently, instead of being eluted, GST-hCD83ext was in situ cleaved with thrombin 
while it bound to the GST-affinity column medium and the hCD83ext moiety was released 
into the bulk liquid phase containing thrombin. Finally, the liquid mixture was processed 
with anion exchange chromatography so that thrombin, other contaminant proteins, and 
endotoxin could be removed for hCD83ext purification. Ultrafiltration was conducted to 
concentrate this fraction and the final hCD83ext product with a high purity was obtained. To 
optimize the in situ cleavage of GST-hCD83ext, the optimum thrombin concentration and the 
cleavage time were determined. More than 95% of GST-hCD83ext was cleaved when the 
thrombin concentration was above 10 Uthrombin/mL column medium, which was eventually 
designated as the optimum thrombin concentration for conducting in-situ cleavage. With 
such a relatively low thrombin concentration, the incubation time was prolonged to 2.5 h to 
ensure complete cleavage. It appeared that hCD83ext was the only protein minimally 
interacting with the anion-exchange medium under this operating condition and a pool of the 
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flowthrough containing extremely pure and low-endotoxin hCD83ext was collected and 
concentrated by ultrafiltration [7]. 
The purified hCD83ext, formulated either in the presence or absence of 50% glycerol, 
tended to degrade when being stored at 4 °C perhaps due to the intrinsic instability of this 
protein molecule. Therefore, the protein had to be stored at -20 °C to ensure its stability. 
Nevertheless, dimerization could still occur under this frozen condition during long-term 
storage. The SDS–PAGE analytical results for hCD83ext samples from different batches, 
hence with different storage ages, are summarized in Figure 3.1. Though these samples 
showed an identical pattern when analyzed by reduced SDS–PAGE (Figure 3.1A), they 
showed different patterns in term of the dimer composition when analyzed by non-reduced 
SDS–PAGE (Figure 3.1B). Generally, the dimer composition increased monotonically with 
the sample age, indicating the progressive conversion of monomer to dimer under this 
storage condition. Note that there were at least two different monomer forms (lane 6, Figure 
3.1B) and three different dimer forms (lanes 3 and 7, Figure 3.1B) derived from various 
sample preps. Cys129 has been identified as the key AA residue mediating an intermolecular 
disulfide bond to form hCD83ext dimers [9]. In addition to dimers, protein bands 
corresponding to trimers, tetramers, and even multimers were observed in certain hCD83ext 
samples and these bands were justified to behCD83ext-related when probed with anti-CD83 
antibodies (Figure 3.2), implying other cysteine residues could also mediate unconventional 
disulfide bonds for multimerization.  
The structural change of hCD83ext was further investigated using a sample stored at 4 °C for 
15 days and the analytical results are summarized in Figure 3.3. There was slight degradation 
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and significant dimerization over the storage period (Figure 3.3A and B). The far-UV CD 
spectra of 0-day and 15-day samples (Figure 3.3C) displayed a negative band at 220 nm and 
a positive band of comparable magnitude near 203 nm, which is a typical pattern of β-sheet 
mixed with type II β-turn [82]. This is rather consistent with our prediction of hCD83ext 3-D 
structure, which is comprised by nine antiparallel β-strands in a typical b-sandwich V-type 
immunoglobulin fold (data not shown). 
Though the CD spectra for the two samples appeared to be distinctive, the 
spectroscopic analysis using CDSSTR method [83] only showed a slight difference in β-
sheet content (i.e. 4% α-helix, 23% β-turn, 39% β-sheet and 33% unordered for the 0-day 
sample, 4% α-helix, 23% β-turn, 35% β-sheet and 37% unordered for the 15-day sample). 
Fluorescence emission spectra of the two samples using 295 nm as the excitation wavelength 
were compared in Figure 3.3D. The emission maximum had a slight blue-shift from 352 nm 
(0-day) to 342 nm (15-day), indicating that the tryptophan residues (i.e. W39 and W49) 
became more buried inside the hydrophobic core of the protein molecule when dimerization 
occurred. These results suggest that the structural variation of hCD83ext, associated with 
disulfide bond formation, would be a critical issue for rigorous control of the quality or even 
bioactivity of hCD83ext as a therapeutic protein. 
 
3.4 Discussion 
Due to the intrinsic instability of hCD83ext, the protein needs to be stored under a 

















Figure 3.1 Analysis of various hCD83ext sample lots with (A) reduced SDS-PAGE and (B) 
non-reduced SDS-PAGE. The protein samples were stored at -20 °C and were formulated in 
50% glycerol except the lane-3 sample which was glycerol-free. The lots were made on 
several different dates, therefore had different “ages” (i.e. 4, 3, 3, 2, 10.5, 9.5, 6.5, 6, 6 
months for lanes 2~10, respectively) upon conducting the analysis. The arrows indicated 

































Figure 3.2 Analysis of an hCD83ext sample with (A) reduced SDS-PAGE, (B) non-reduced 
SDS-PAGE, and (C) Western blotting. The SDS gels were stained using silver nitrate in 
order to make higher multimeric species (such as trimer and tetramer) visible. All these 
species were verified to be associated with hCD83ext by Western blotting. Note that a small 
amount of GST exited in the hCD83ext product fraction as a contaminant protein. 
 
 
multimerization via the formation of intermolecular disulfide bonds under this relatively 
oxidative storage condition. There are five cysteine residues (AAs 27, 35, 100, 107, and 129) 
in hCD83ext and Cys129 was identified as the major one mediating the intermolecular 
disulfide bond to form dimers [9]. However, the other four cysteine residues can be involved 
in the formation of intramolecular [9] or even intermolecular disulfide bonds. The multiple 
forms of monomers and dimers in Figure 3.1 could possibly result from different pairing for 
intramolecular disulfide bond formation among these five cysteine residues. Recently, we 





























disulfide bonds using cysteine residues other than Cys129.  Interestingly, in addition to dimer, 
higher multimeric forms (i.e. trimer, tetramer, etc.) were also observed in a few hCD83ext 
samples (Figure 3.2). The results suggest that, though Cys129 is the key residue driving the 
formation of the intermolecular disulfide bond for dimerization, other cysteine residues could 
also be involved in the extensive formation of intermolecular disulfide bonds for 
multimerization.  
Theoretically, the GST-hCD83ext fusion originally harvested from the cytoplasm 
(which is a reductive compartment) of producing cells should not contain any disulfide 
bonds. However, disulfide bond formation could occur in any downstream processing steps 
which were normally conducted in an oxidative environment. In fact, we observed the 
existence of hCD83ext dimers in the post-GST fraction (i.e. the eluent fraction from GST 
affinity chromatographic column after thrombin cleavage) though at a small amount (data not 
shown). With the potential application of hCD83ext as a therapeutic protein, this 
posttranslational issue of disulfide bond formation during downstream processing could have 
an impact on the product quality and needs to be properly addressed. In addition, developing 
a proper formulation recipe leading to a specific pattern of disulfide bond formation for 






























Figure 3.3 Comparison in structural change of an hCD83ext sample over 15-day storage at 0 
°C using (A) reduced SDS-PAGE, (B) non-reduced SDS-PAGE, (C) CD spectroscopy, and 

















































Structural Identification of Recombinant Human CD83 Mutant 
Variant as a Potent Therapeutic Protein 
The work in this chapter was published in Protein Expr. Purif. 73 (2010) 140-146. 
Authors: Lin Zhang, Niju Narayanan, Stephen R. Brand, Charles A. Nicolette, Miren 
Baroja, Jacqueline Arp, Hao wang, Murray Moo-Young, C. Perry Chou 
Declaration: I initiate and conduct the structural study of wild-type and mutant variants of 
hCD8ext, which is the main content of this chapter. Niju Narayanan kindly derives the 
mutant variant with mutation of Cys100Ser. Miren Baroja, Jacqueline Arp and Hao wang in 




There are five cysteine residues (AAs 27, 35, 100, 107, and 129) in the recombinant 
hCD83ext and, theoretically, any one of them can be involved in the aberrant formation of 
disulfide bonds, either intermolecularly or intramolecularly. Previously, Cys129 was identified 
as the major cysteine mediating the intermolecular disulfide bond to form hCD83ext dimers 
and the Cys129Ser mutant derivative still had comparable bioactivity [84] without forming 
dimers [9]. Nevertheless, the protein product of this mutant derivative produced in our lab 
had an inconsistent bioactivity (unpublished data), similar to the case of wild-type hCD83ext. 
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The presence of higher multimeric forms, such as trimers and tetramers, for wild-type 
hCD83ext [7] suggests that cysteine residues other than Cys129 could also be involved in 
disulfide bond formation.  
In this study, we re-examined and modified the sample preparation protocol to 
analyze hCD83ext products. In contrast to a previous report [9], our results based on sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion 
chromatography (SEC) demonstrate that the Cys129Ser mutant derivative (i.e. M5) can still 
form dimers, presumably via the formation of intermolecular disulfide bond(s) between 
cysteine residues other than Cys129. Possible underlying reasons for such analytical 
discrepancy were proposed. Most importantly, we identified another mutant derivative, 
Cys100Ser mutation (i.e. M3), which remains monomeric even after prolonged storage. 
 
4.2 Materials and Methods 
4.2.1 Bacterial Strains and Plasmids 
Plasmid pGEX2ThCD83ext, containing the cDNA encoding hCD83ext (i.e. AA 20-145 of 
hCD83ext) fused with the gst gene, was used for the expression of GST-hCD83ext regulated 
by the IPTG-inducible tac promoter [8]. Due to the design of a thrombin cleavage site at the 
junction between GST and hCD83ext, the final hCD83ext product has four extra AAs, i.e. 
Gly-Ser-Pro-Gly, in the amino terminus and this modification was presumed to have no 
effect on hCD83ext bioactivity [8]. Plasmid pGEX2ThCD83ext_mut129_CtoS, a derivative 
from pGEX2ThCD83ext, was used for the expression of GST-hCD83ext_mut129_CtoS (i.e. 
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GST-M5). Both pGEX2ThCD83ext and pGEX2ThCD83ext_mut129_CtoS were gifts from 
A. Steinkasserer. Plasmid pGEX2ThCD83ext_mut100_CtoS, another pGEX2ThCD83ext 
derivative constructed in this study, was used for the expression of GST-
hCD83ext_mut100_CtoS (i.e. GST-M3). To construct the plasmid, site-directed mutagenesis 
was performed using a QuikChange® Multi Site-Directed Mutagenesis kit (Stratagene, La 
Jolla, CA, USA) with the PCR template of pGEX2ThCD83ext and the primer of 5'-
ATCCGAAACACTACGAGCTCCAACTCGGGG-3' (nucleotidic mutations are denoted in 
Italic). The primer contains the Cys100Ser mutation (in bold) and a silent mutation 
generating an extra SacI restriction site (underlined). Purification of plasmid DNA was 
performed using a spin-column kit (BD Biosciences Clontech, Mississauga, ON, Canada). 
Plasmid transformation was carried out using a chemical method [85]. Escherichia coli 
BL21(DE3)(pLysS) (Novagen, New Canaan, CT, USA) was used as the expression host.  
4.2.2 Production of hCD83ext Variants 
The production of hCD83ext variants, i.e. wild-type hCD83ext, M5, and M3, was performed 
using the fermentation and downstream processing protocols developed previously [7]. The 
protein products were formulated in 50% glycerol and stored at -20 °C. 
4.2.3 Analytical Methods 
Protein concentration for hCD83ext variants was quantified by the absorbance at 280 nm 
using the extinction coefficient of 1.1 OD280-mL-mg-1cm-1. Limulus Amoebocyte Lysate 
(LAL) assay was carried out to measure the endotoxin level using a commercial kit from 
Cambrex (East Rutherford, NJ, USA).  
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SEC was performed using ÄKTApurifer (GE Healthcare, Baie d'Urfé, QC, Canada) 
equipped with a TSK-GEL® G2000SWXL column (Tosoh Bioscience LLC, 
Montgomeryville, PA, USA) and a UV detector. The mobile phase was 100 mM phosphate 
buffer (pH 7.0) with 50 mM NaCl at a flow rate of 0.7 ml/min. Protein samples, either 
reduced with dithiothreitol (DTT) or non-reduced, were loaded and subsequently detected at 
280 nm.  
SDS-PAGE and Western blotting were performed using the protocols described 
previously [7]. Where indicated, protein samples (0.1 mg/mL, pH 7.3) were pretreated with 5 
mM N-ethylmaleimide (NEM) at room temperature for 30 min for alkylation of free 
sulfhydryl groups. Samples for reducing and non-reducing SDS-PAGE were prepared by 
mixing NEM-pretreated protein samples with 2X sample buffer (65 mM Tris-HCl, 25% v/v 
glycerol, 2% w/v SDS, 0.01% w/v bromophenol blue) respectively with and without 5% v/v 
2-mercaptoethanol. All SDS-PAGE samples were boiled for 4 min after mixing with 2X 
sample buffer.  
The number of free sulfhydryl groups was determined according to the Ellman’s 
assay [35, 86] by mixing 100 µL protein sample and 20 µL 5, 5’-Dithio-bis-(2-nitrobenzoic 
acid) (DTNB) (4 mg/mL in 0.1 M phosphate buffer, pH 8.0) with 1 mL reaction buffer (0.1 
M phosphate buffer, pH 8.5). The reaction was carried out for 15 min at room temperature. 
The absorbance at 412 nm was measured and the concentration of sulfhydryl groups was 




Far-UV circular dichroism (CD) spectra of protein samples were obtained using a 
spectropolarimeter (Jasco-815; Jasco, Japan). Fluorescence emission spectra (over the range 
of 300 ~ 420 nm) of protein samples were obtained using a spectrofluorometer (FP-6500; 
Jasco, Japan) with an excitation wavelength at 295 nm. All the spectroscopic measurements 
were made at a room temperature of 23 °C. 
Biological activity of hCD38ext variants was evaluated using an in vitro assay based 
on the determination of the protein’s ability to inhibit tumor necrosis factor alpha (TNF-α) 
production by lipopolysaccharide/interferon-gamma (LPS/IFN-γ) stimulated peripheral blood 
mononuclear cells (PBMCs). Specifically, PBMCs from cynomolgus macaques (Macaca 
fascicularis) were isolated and pretreated with hCD83ext variants under different 
concentrations (i.e. 0.5, 5, 25, and 100 μg/mL) for 12 h. The cells were then activated with 
LPS (1 μg/mL) and IFN-γ (100 U/mL) in the presence of Brefeldin A (4 μg/mL) for 6 h and 
intracellularly stained for TNF-α using a commercial Fix/Perm kit. Flow cytometry was 
performed to quantify the amount of TNF-α production using monocytes. 
 
4.3 Results 
4.3.1 Structural Analysis Using SDS-PAGE 
Due to the presence of free sulfhydryl groups and disulfide bonds in the product samples of 
hCD83ext variants, we hypothesized that thiol-disulfide exchange could possibly occur 
during denaturing heat treatment via a mechanism known as disulfide scrambling [51, 56]. 
As a result, the intermolecular disulfide bonds could be broken by the free sulfhydryl group 
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on another cysteine residue to result in the formation of an intramolecular disulfide bonds, 
and thereby release hCD83ext monomers. If this were to occur, the observed ratio of 
monomer to dimer upon the SDS PAGE analysis would not be representative of the actual 
ratio of monomer to dimer that was present prior to denaturation. To prevent such disulfide 
scrambling, NEM alkylation of free sulfhydryl groups was conducted prior to protein 
denaturation. Using different sample preparation protocols to process four hCD83ext samples 
(two independent wild-type samples, M5, and M3), the results of SDS-PAGE analysis under 
both reducing and non-reducing conditions are summarized in Figure 4.1. While there was 
only a single band for all the samples using reducing SDS-PAGE (Figure 1A), non-reducing 
SDS-PAGE enabled the analysis of various monomeric and multimeric forms (Figure 4.1B). 
By comparing the results of non-NEM-treated samples (lanes 2-5, Figure 4.1B) and the 
corresponding NEM-treated samples (lanes 6-9), it is clear that the dimer/monomer ratio 
increased significantly as a result of the NEM treatment, particularly for the two wild-type 
samples (lane 5 vs. 9) and M5 (lane 2 vs. 6). These analytical discrepancies can be associated 
with disulfide scrambling which broke intermolecular disulfide bonds within dimers and 
higher multimers to form intramolecular disulfide bonds. In other words, NEM-treated 
samples analyzed with non-reducing SDS-PAGE reflected the actual species distribution in 
the protein sample. Interestingly, multimerization was not observed with M3 (lane 7), unlike 
the wild-type and M5 species. There were at least two monomeric bands observed for M5 
(lane 2) and M3 (lane 3) without NEM treatment, but the two bands merged into one when 
samples were treated with NEM (lanes 6 and 7). This result may be due to disulfide 
scrambling between free sulfhydryl groups and intramolecular disulfide bonds within 
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monomers, which can be also prevented by NEM treatment. We also note that the mobility of 
M3 monomer (lane 7) was approximately the same as that of wild-type monomer (lanes 8 
and 9) but different from that of M5 monomer (lane 6). Such mobility differences 
presumably resulted from different intramolecular disulfide patterns since all reduced 
monomers had the same mobility (lanes 6-9 in Figure 4.1A). 
Interestingly, the above-mentioned effects associated with the NEM treatment were 
no longer observed when samples were treated with NEM after protein denaturation [i.e. no 
analytical discrepancies were observed between samples without NEM treatment (lanes 2-5) 
and samples with NEM treatment after protein denaturation (lanes 10-13)], suggesting that 
disulfide scrambling occurred primarily during heat treatment and, therefore, the NEM 
treatment has to be performed prior to protein denaturation.  
4.3.2 Structural Analysis Using SEC 
To further verify the above results obtained based on non-reducing SDS-PAGE (particularly 
in monomer/dimer distribution), both reduced and non-reduced protein samples were 
subjected to SEC analysis under their native condition and the results are summarized in 
Figure 4.2. The monomeric and dimeric forms are represented by the two peaks eluted at 
12.6 and 11.5 min, respectively. Apparently, M3 is the only variant that did not form dimers 
whereas dimerization was observed for both wild-type and M5. The monomer/dimer 
distributions obtained by SEC analysis were quantitatively more consistent with those 
obtained by non-reducing SDS-PAGE using samples with proper NEM treatment (i.e. lanes 
6-9 in Figure 4.1B). While SEC was adopted here for qualitative or even quantitative analysis 
of dimer/monomer distribution, it could not be used for differentiating different monomeric 
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Figure 4.1 Analysis of four hCD83ext products treated with various sample preparation 
protocols using reduced SDS-PAGE (Panel A) and non-reduced SDS-PAGE (Panel B). For 
both panels: Lane 1/ molecular weight markers; lanes 2, 6, 10/ M5; lanes 3 7, 11/ M3; lanes 
4, 8, 12/ wild-type-1; lane 5, 9, 13/ wild-type-2. Lanes 2~5 are samples with no NEM-
treatment; lanes 6~9 are samples with NEM-treatment prior to heat denaturation; lanes 10~13 










































Figure 4.2 Analysis of four hCD83ext products using SEC. The elution profiles for both 
reduced (with DTT treatment) and non-reduced (without DTT treatment) are shown. Panel 


























































4.3.3 Monitoring of Conformational Changes 
Molecular behavior of the three hCD83ext variants was compared by monitoring the 
conformational changes under a frozen storage condition and the results are summarized in 
Figures 4.3 and 4.4. While the three protein samples shared an identical band pattern using 
reducing SDS-PAGE (Figure 4.3A~4.3C), they had rather distinctive dimerization profiles 
over the storage period using non-reducing SDS-PAGE with proper NEM treatment (Figure 
4.3D~4.3F). No dimerization was observed for M3, whereas progressive dimerization was 
observed for both wild-type and M5. The rate of dimerization for M5 was comparable to that 
of wild-type. Notice that there are at least two distinctive dimer bands and even several 
higher multimers for M5, implying a more complex scenario for M5 multimerization. Again, 
the mobility of M5 monomer band was significantly lower than that of wild-type or M3 
possibly due to their different disulfide patterns. 
Structural monitoring and comparison of hCD83ext variants were also performed 
using far-UV CD and fluorescence spectra and the results are summarized in Figure 4.4. 
Interestingly, M3 displayed certain major spectroscopic changes (i.e. CD spectra at 195, 203 
and 220 nm and fluorescence spectra at λmax of 343 nm) during the 15-day frozen storage 
whereas only minor changes were observed for both wild-type and M5. The results suggest 
that dimerization could not be properly monitored using these two spectroscopic analyses. 
Notice that the significant increase in fluorescence intensity and the shift of λmax for M3 as 
compared to wild-type imply that the protein conformational changes associated with the 
























Figure 4.3 Structural monitoring and comparison for M3 (Panels A and D), wild-type (Panels 
B and E), and M5 (Panels C and F) products stored under -20 °C using reduced SDS-PAGE 
(Panels A, B, and C) and non-reduced SDS-PAGE (Panels D, E, and F). Panels A and D: 
Lane 1/ molecular weight markers; lanes 2~5/ samples taken on day 0, 1, 7, and 15, 
respectively. Panel B and E: Lane 1/ molecular weight markers; lanes 2~6/ samples taken on 
day 0, 1, 2, 6, and 10, respectively. Panel C and F: Lane 1/molecular weight markers; lanes 












































































Figure 4.4 Structural comparison for M3, wild-type, and M5 products stored under -20 °C 
using CD (panels A and B) and fluorescent spectroscopy (panels C and D). Panels A and C: 
spectra of day-0 samples; panels B and D: spectra of day-15 samples. 
4.3.4 Bioactivity Comparison 
Based on the above analytical results, M3 appeared to be the most structurally stable among 
the three hCD83ext variants and was not subjected to multimerization during the frozen 
storage. The bioactivity of the three hCD83ext variants was compared using an in vitro 









































































Figure 4.5 The ability of hCD83ext variants (i.e. wild-type, M5 and M3) to inhibit TNF-α 
production by LPS/IFN-γ stimulated primate PBMCs. The inhibition was quantified by either 
the percentage of monocytes that produce TNF-α (panel A) or by the mean level of TNF-α 




















































































While both wild-type and M5 could inhibit TNF-α production by LPS/IFN-γ stimulated 
PBMCs when present at high concentrations (e.g. 25 or 100 μg), M3 displayed the inhibitory 
effect at all concentrations. 
 
4.4 Discussion  
Since therapeutic protein products are often subject to an extensive storage period before 
clinical administration, their quality can be jeopardized by possible conformational changes 
and other factors during the storage period. Theoretically, the GST-hCD83ext fusion protein 
originally harvested from E. coli cytoplasm (which is a reductive compartment) should 
contain no disulfide bonds. It is clear that aberrant disulfide bonds, either intramolecular or 
intermolecular, can be formed in vitro during downstream processing and/or storage. Such 
unregulated disulfide bond formation could potentially limit consistent bioactivity. Hence, 
identifying hCD83ext variants that can avoid the formation of aberrant disulfide bonds is 
warranted. 
There are five cysteine residues in wild-type hCD83ext and, theoretically, any 
cysteine pair spatially close to one another can form a disulfide bond. We hypothesized that 
the formation probability can be explicitly determined by the transient protein structure under 
storage conditions and/or intrinsically encoded by protein sequence. Up to now, there is 
rather limited knowledge and experimental demonstration as to how protein conformation 
and/or protein sequence can affect the formation of aberrant disulfide bonds. Since disulfide 
bond formation is considered an uncontrolled variable, all cysteine residues become a 
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legitimate target for protein manipulations aimed at improving the robustness and 
consistency of the manufacturing process. The effects of two mutations, i.e. Cys100Ser and 
Cys129Ser, on hCD83ext conformation, multimerization, and bioactivity were specifically 
investigated in this study. 
Our results suggest that, for proper analysis by non-reducing SDS-PAGE, hCD83ext 
protein samples should be treated with NEM prior to protein denaturation to avoid disulfide 
scrambling by which the intermolecular disulfide bonds within hCD83ext multimers 
(particularly dimers) could be broken with concomitant formation of intramolecular disulfide 
bonds. The modified protocol led to an analytical discrepancy with the previous report [9]. 
Notably, there was only a faint dimeric band for M5 without NEM treatment (lane 2, Figure 
4.1B), but the signal for the dimeric band became much stronger for M5 with NEM treatment 
(lane 6, Figure 4.1B). M5 dimerization was observed consistently using both non-reducing 
SDS-PAGE and SEC in this study. The results suggest that disulfide scrambling occurred and 
consequently all intermolecular disulfide bonds connecting M5 monomers were broken, 
leading to the analytical misinterpretation. Structurally, the intermolecular disulfide bond for 
M5 dimers could be rather unique and close to free sulfhydryl group(s) to cause disulfide 
scrambling. On the other hand, there could be more than one type of intermolecular disulfide 
bond linking monomers of wild-type hCD83ext, consistent with what was suggested in our 
previous report [7]. The intermolecular disulfide bond similar to the one formed within M5 
dimers was scrambled easily, whereas others (which might be distant from free sulfhydryl 
groups) remained intact. The current results suggest that Cys129 in wild-type hCD83ext could 
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be involved in forming intermolecular disulfide bonds that are distant from free sulfhydryl 
groups. 
Consistent with the results for structural monitoring of the final product samples of 
hCD83ext variants under frozen storage conditions (Figure 4.3), dimerization of M5 was 
further confirmed whereas no dimerization was observed with M3, even after long-term 
storage. These data confirm that the molecular behavior for therapeutic proteins can be 
significantly altered by minor structural changes such as single amino acid mutations. 
Apparently, Cys100 is a key amino acid involved in the formation of intermolecular disulfide 
bonds for hCD83ext multimerization. Hence, Cys100 in M5 could be involved in forming 
intermolecular disulfide bonds close to free sulfhydryl groups, leading to effective disulfide 
scrambling. However, cysteine residues other than Cys100 could still be involved in the 
formation of aberrant disulfide bonds. The structural effects of Cys→Ser mutation for the 
other three cysteine residues (i.e. Cys27, Cys35, Cys107) are currently under investigation. 
Preliminary results indicate that dimerization still occurs to the hCD83ext variant with any of 
these single mutations. 
Theoretically, to ensure the consistent quality of therapeutic products, protein 
molecules should be optimally designed and produced in such a way as to incorporate a fixed 
disulfide pattern and to prevent the formation of aberrant disulfide bonds. The consistent 
molecular behavior without dimerization over an extensive storage period made M3 a 
feasible protein therapeutic candidate. As shown by the current results, excellent in vitro 
biological activity was observed for M3. Recently, therapeutic bioactivity for M3 was 
successfully demonstrated in several in vivo studies using rodent models (unpublished data). 
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Though no dimerization was detected by SDS-PAGE and SEC for M3, the conformational 
changes associated with spectroscopic analyses and the decreasing number of free sulfhydryl 
groups (data not shown) suggests the possible formation of intramolecular disulfide bond(s) 
within M3 monomers. Notice that M3 monomers with different intramolecular disulfide 
patterns cannot be differentiated using non-reducing SDS-PAGE. Fortunately, it appears that 




Effect of Aberrant Disulfide Bond Formation on Protein 
Conformation and Molecular Property of hCD83ext 
The work in this chapter was published in Pure Appl. Chem. 82 (2010): 149-159. 
5.1 Introduction 
Theoretically, in vivo disulfide bond formation should be more consistent than in vitro 
formation since biological cells are able to maintain their intracellular environment rather 
steadily. In addition, intracellular disulfide bonds can be consistently processed by the Dsb-
family members with rigorous formation mechanisms [47]. Though E. coli contains an 
oxidative periplasm in which disulfide bonds can be formed, heterologous protein expression 
targeting this compartment can be possibly limited by ineffective translocation. It is known 
that disulfide bond formation hardly occurs in the reductive cytoplasm of wild-type E. coli. 
However, the double mutation on the genes encoding thioredoxin reductase (trxB) and 
glutathione reductase (gor) [or glutathione synthetase (gshB)] can convert the reductive 
cytoplasm into an oxidative one, which offers an alternative expression compartment for 
proteins requiring disulfide bonds [87]. 
In this study, we used two E. coli B strains, i.e. BL21 and Origami B respectively 
with reductive and oxidative cytoplasm, to produce hCD83ext. With these two product 
preparations for parallel comparison, we demonstrated the significant effect of aberrant 
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disulfide formation on protein conformation which subsequently affected the molecular 
property of this therapeutic product. 
 
5.2 Materials and Methods 
5.2.1 Bacterial Strains and Plasmids 
The plasmid pGEX2ThCD83ext containing the hCD83ext cDNA fused with the gst gene was 
used as the vector for expression of GST-hCD83ext under the regulation of an IPTG-
inducible tac promoter [8]. Due to the design of a thrombin cleavage site at the junction 
between GST and hCD83ext, the final hCD83ext product has four extra AAs, i.e. Gly-Ser-
Pro-Gly, in the amino terminus and this modification was presumed to have no effect on the 
biochemical property of hCD83ext. BL21(DE3) and its trxB and gor double mutant 
derivative of Origami B(DE3) (EMD Biosciences/Novagen, La Jolla, CA, USA) were used 
as the expression hosts.  
5.2.2  Cultivation and Downstream Processing 
The production and purification of hCD83ext were conducted using the protocols developed 
previously [7].   
5.2.3 Sample Treatment for Analyses 
The culture sample was appropriately diluted with saline solution for measuring cell density 
at OD600 with a spectrophotometer (DU®520, Beckman Coulter, Fullerton, CA, USA). For 
the preparation of cell extract, cells in the amount of 30 OD600-units (defined as ‘OD600×mL’) 
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were centrifuged at 6000×g and 2 °C for 10 min. The cell pellet was resuspended in 0.75 mL 
phosphate-buffered saline (pH 7.3), sonicated intermittently (i.e. 0.5 s/0.5 s on/off) for 4 min 
using an ultrasonic processor (Misonix, Farmingdale, NY, USA) with a microtip, and then 
centrifuged at 15,000×g and 2 °C for 15 min to remove cell debris. The supernatant 
containing soluble proteins was used for various analyses, including GST assay, SDS-PAGE, 
and Western blotting. The pellet containing insoluble proteins and cell debris was washed 
with phosphate buffer, resuspended in TE/SDS buffer (10 mM Tris HCl, pH 8.0, 1 mM 
EDTA, 1% SDS), and heated to 100 °C for 5 min for dissolution. The protein content of the 
pellet was analyzed as the insoluble fraction. 
5.2.4 Analytical Methods 
GST was assayed at ambient temperature using 1-chloro-2,4 dinitrobenzene (CDNB) and 
glutathione as the substrates. GST (or its fusion) catalyzes the reaction of the two substrates 
to form a conjugate product that can be monitored at 340 nm. One unit (UGST) is defined as 
the amount of enzyme that causes an increase in absorbance at 1 OD340/min. The protein 
concentration of purified hCD83ext was quantified with its absorbance at 280 nm (OD280) 
and the extinction coefficient of 1.2 OD280-ml/mg/cm. The number of titratable free 
sulfhydryl group was determined using the Ellman assay [51]. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed in a Mini-PROTEAN®II electrophoresis cell (Bio-Rad) under both reducing and 
non-reducing conditions using a 12.5% polyacrylamide separating gel stacked by a 4% 
polyacrylamide stacking gel. Reduced and non-reduced protein samples were prepared using 
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the 2X sample buffer respectively supplemented with 5% 2-mercaptoethanol and 20 mM N-
ethylmaleimide (NEM). Electrophoresis was conducted at a constant voltage of 200 V for 
approximately 45 min. The gel was stained with Coomassie blue or silver nitrate and dried. 
The dried gel was scanned. Compositions of monomer and dimer were quantified by 
measuring the pixels of their representing bands in the scanned gel images using UN-SCAN-
IT software (Silk Scientific, Orem, UT, USA).  
To conduct Western blotting, the proteins on the polyacrylamide gel were 
electroblotted to a PVDF membrane after SDS-PAGE using a Mini Trans-Blot® Cell (Bio-
Rad) according to a standard protocol [80]. The electrophoretic transfer was conducted at a 
constant voltage of 100 V for 1 h. Protein-antibody hybridization was performed as described 
by Sambrook et al. [81]. The purified hCD83ext was used as an antigen for raising 
polyclonal anti-CD83 antibodies in rabbits. The secondary antibody was goat anti-rabbit IgG 
conjugated with horseradish peroxidase (Sigma-Aldrich). All hCD83-related polypeptides 
(e.g. GST-hCD83ext and hCD83ext) were detected by a colorimetric method using 3,3'-
diaminobenzidine tetrahydrochloride (DAB) as the substrate. The processed membrane was 
scanned.  
Far-UV circular dichroism (CD) spectra of protein samples were obtained using a 
spectropolarimeter (Jasco-815; Jasco, Japan). Fluorescence emission spectra (over the range 
of 300 ~ 420 nm) of protein samples were obtained using a spectrofluorometer (FP-6500; 
Jasco, Japan) with an excitation wavelength at 295 nm. All the spectroscopic measurements 




5.3.1 Bacterial Cultivation for hCD83ext Expression 
Using BL21(DE3) and Origami B(DE3) as the host, cultivation for the expression of GST-
hCD83ext was conducted in a bench-top bioreactor under identical operating conditions and 
the comparative results are summarized in Figure 5.1. The growth rate of recombinant 
Origami B(DE3) was significantly lower than that of recombinant BL21(DE3), resulting in 
approximately 20% reduction in both final cell density and specific GST activity (Panels A 
and B of Figures 5.1). The reduction in growth rate for Origami strains was previously 
reported and attributed to possible malfunction of many cytoplasmic proteins under an 
oxidative condition [73]. However, the GST activity might not reflect the actual expression 
level of GST-hCD83ext since SDS-PAGE results indicated otherwise (Figure 5.1C, Lanes 2 
vs. 4 and Lanes 6 vs. 8) and this discrepancy appeared to be reproducible, suggesting that the 
oxidative environment in Origami B(DE3) could result in a certain level of reduction in GST 
activity. 
Notice that, upon SDS-PAGE analysis, GST-hCD83ext expressed in Origami B(DE3) had a 
higher electrophoretic mobility under a non-reducing condition compared to that of its 
corresponding monomeric form under a reducing condition (Figure 5.1C, Lanes 4 vs. 8), 
indicating that certain intramolecular disulfide bond(s) formed in the oxidative cytoplasm. 
Unsurprisingly, such observation was not made when BL21(DE3) was used as the expression 
host since disulfide bonds cannot be formed in the reductive cytoplasm of wild-type E. coli. 
In addition, GST-hCD83ext expressed in both strains was not completely soluble though the 
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expression in Origami B(DE3) was slightly more soluble than that in BL21(DE3) (Figure 











Figure 5.1 Comparison of bioreactor cultivation performance for the production of GST-
hCD83ext in two host strains: Cell density (Panel A), specific GST activity (Panel B), and 
intracellular protein analysis of both soluble and insoluble fractions under reducing and non-
reducing conditions with SDS-PAGE (Panels C) and Western blotting (Panels D) for the 
culture samples taken prior to induction and at 6 h post-induction time are shown. Panel C: 
Lanes 1, 2, 5, 6, 9 and 10 represent samples produced by BL21(DE3), whereas lanes 3, 4, 7, 
8, 11, and 12 represent samples produced by Origami B(DE3). Arrows represent the protein 
bands corresponding to disulfided and non-disulfided hCD83ext monomers. Panel D: All 
lanes represent culture samples taken at 6 h post-induction time. Arrows represent the protein 













































































Figure 5.1 (Continued) 
0      6       0      6              0       6       0   6      0       6      0     6 h (post-induction time)














































intermolecular disulfide bond(s) in Origami B(DE3) and these bands were verified to be 
associated with hCD83ext using Western blotting (Lane 4, Figure 5.1D). 
5.3.2 Comparison of hCD83ext Conformation 
The expressed GST-hCD83ext from both production strains was trapped with GST-
affinity chromatography and was subject to on-column cleavage with thrombin to release the 
hCD83ext moiety, which was then polished with anion exchange chromatography, 
concentrated, and formulated in 50% glycerol for subsequent structural characterization. It 
appeared that the yield for the polishing step was moderately increased by in vivo disulfide 
bond formation (data not shown). Far-UV CD and fluorescent spectra of hCD83ext produced 
by the two strains were compared and the results are summarized in Figure 5.2. Both 
hCD83ext samples displayed a CD spectrum with a negative band at 220 nm and a positive 
band near 203 nm (Figure 5.2A), which is a typical pattern for β-sheets mixed with type II β-
turns [82]. The spectrum of hCD83ext produced by BL21(DE3) had a lower band at 203 nm 
and a deeper trough at 220 nm, compared to that of hCD83ext produced by Origami B(DE3). 
Based on the spectroscopic simulation using the K2D method [88], the two hCD83ext 
preparations had slightly different compositions in the secondary structure, i.e. the ratio of α-
helix: β-sheet: unordered structure at 9%: 43%: 48% for hCD83ext produced by BL21(DE3) 
and 4%: 48%: 48% for hCD83ext produced by Origami B(DE3). Since hCD83ext has two 
tryptophan residues (i.e. AAs 39 and 49), the emission spectrum reflecting the local 
environment near the tryptophan residues can shed light on the tertiary structure. The 
maximum emission intensity (at 345 nm) of hCD83ext produced by BL21(DE3) was 
approximately 3-fold that (at 350 nm) of hCD83ext produced by Origami B(DE3) with a 
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Figure 5.2 Analysis of protein structure for fresh hCD83ext produced by two host strains 




























Though significant conformational differences between the two hCD83ext variants, 
the SDS-PAGE analysis revealed a rather similar pattern (Lane 2 in Panels A~D of Figure 
5.3) except the observation that hCD83ext produced by BL21(DE3) had two monomeric 
forms (Lane 2, Figure 5.3C) whereas hCD83ext produced by Origami B(DE3) only had a 
single monomeric form (Lane 2, Figure 5.3D). On the other hand, the number of titratable 
free sulfhydryl group was 0.96 and 0.63 under a native condition for hCD83ext produced by 
BL21(DE3) and Origami B(DE3), respectively (Panels A and B of Figure 5.4).  
5.3.3 Comparison of hCD83ext Molecular Property 
The molecular properties of the two hCD83ext variants were compared by monitoring the 
conformational changes under storage conditions (either -20 °C or room temperature) and the 
results are summarized in Figures 5.3 and 5.4. While the two protein samples had an identical 
band pattern upon reducing SDS-PAGE (Panels A and B of Figure 5.3), two rather different 
dimerization profiles over the incubation period were observed upon non-reducing SDS-
PAGE, particularly for the samples stored at -20 °C (Panels C and D of Figure 5.3). 
Compared to hCD83ext produced by BL21(DE3), hCD83ext produced by Origami B(DE3) 
appeared to have a higher tendency for initial dimerization. The monomeric doublet 
corresponding to hCD83ext produced by BL21(DE3) disappeared over the storage period. 
The rate of dimerization for hCD83ext appeared to increase noticeably when incubated at 
room temperature, particularly for hCD83ext produced by BL21(DE3). Notice that, while the 
hCD83ext monomers corresponding to the two protein samples were rather stable at room 
temperature, the dimers started to degrade after 2 days of incubation (Lanes 8, 9 and 10 in 















Figure 5.3 Monitoring and comparison of molecular property for hCD83ext produced by two 
host strains with reducing SDS-PAGE (Panels A and B), non-reducing SDS-PAGE (Panels C 
and D), CD spectroscopy (Panels E and F), and fluorescence spectroscopy (Panels G and H): 
Samples up to 30-day storage at -20 °C and 10-day storage at room temperature were 
analyzed. Panels A, C, E, and G represent hCD83ext samples produced by BL21(DE3), 
whereas Panels B, D, F, and H represent hCD83ext samples produced by Origami B(DE3). 
Panels A~D: lane 1/ molecular weight markers; lane2/ day 0; lanes 3 ~ 6 and 11/ -20 °C 
samples taken on day 1, day 2, day 6, day 10, and day 30, respectively; lanes 7 ~ 10/ room 
temperature samples taken on day 1, day 2, day 6, and day 10, respectively. The insets at 
upper right in Panel C and D represent the time profiles for dimerization of hCD83ext stored 
at -20 °C. Such quantification was not conducted for samples stored at room temperature 
since hCD83ext dimer appeared to be unstable. 
 





































Figure 5.3 (Continued) 












































































Figure 5.3 (Continued) 
 
 
The far-UV CD spectra with respect to storage time suggest that both hCD83ext 
variants did not experience significant changes in the secondary structure (Panels E and F of 
Figure 5.3) during the storage, even in the presence of dimerization and dimer degradation. 
Results of fluorescence spectra revealed a slight red-shift upon 10 days of incubation at room 












































































Figure 5.4 Time profiles for the number of titratable free sulfhydryl group in hCD83ext 
produced by BL21(DE3) (Panel A) and Origami B(DE3) (Panel B): Profiles for samples 



























































The maximum intensity of emission spectrum for hCD83ext produced by BL21(DE3) 
monotonically decreased with incubation time; whereas that for hCD83ext produced by 
Origami B(DE3) appeared to fluctuate with a significant increase for the 30-day sample 
stored at -20 °C. The decreasing trend in the number of titratable free sulfhydryl group 
suggests that disulfide bonds were continuously being formed (Figure 5.4). Overall, the 




There are five cysteine residues in hCD83ext and it was reported that hCD83ext can form 
dimers in vitro via a major intermolecular disulfide bond at Cys129 [9]. However, in vivo 
disulfide bond formation within GST-hCD83ext at the protein expression level was not 
previously explored. The present results show that GST-hCD83ext fusion contained no 
disulfide bonds when expressed in the reductive cytoplasm of BL21(DE3), but contained 
intramolecular or even intermolecular disulfide bond(s) when expressed in the oxidative 
cytoplasm of Origami B(DE3). The Cys27 residue in the hCD83ext moiety could play a key 
role for such in vivo disulfide bond formation since no monomer with a higher 
electrophoretic mobility was observed for the GST fused with the Cys27 mutant derivative of 
hCD83ext expressed in Origami B(DE3) [89]. Though the precise location(s) of such in vivo 
disulfide bond formation was not characterized, the protein conformation and molecular 
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properties of the final hCD83ext product were significantly affected by this post-translational 
processing at the protein expression level. 
With respect to the protein conformation, it appeared that the two hCD83ext variants 
had rather distinct secondary structures (based on CD spectra) and tertiary structures (based 
on fluorescent spectra) though SDS-PAGE revealed a very similar pattern. Since the 
expression host was the only difference in Materials & Methods upon producing these two 
variants, it is plausible to assume that the structural differences could result from different 
disulfide patterns, namely hCD83ext produced by Origami B(DE3) might contain an extra 
unconventional intramolecular disulfide bond(s) bridged in vivo. Analysis of hCD83ext 
sequence reveals an immunoglobulin (Ig) domain with a conserved disulfide bond between 
Cys35 and Cys107. In addition, our prediction of 3-D structure (data not shown) also suggests 
Cys27 and Cys100 are spatially close enough to form a possible disulfide bond. However, the 
argument cannot be verified by reducing SDS-PAGE since the major monomeric bands for 
both variants had approximately the same electrophoretic mobility (Panels C and D of Figure 
5.3). Interestingly, an extra monomeric band with a lower electrophoretic mobility was 
observed in day-0 sample for hCD83ext produced by BL21(DE3) and we speculated that it 
could represent un-disulfided hCD83ext. If this argument were true, the major monomeric 
band for hCD83ext produced by BL21(DE3) would also contain a disulfide bond(s), which 
were presumably formed in vitro and rather effectively during downstream processing 
normally conducted in an oxidative environment. To address these technical issues, 
characterization of disulfide pattern for hCD83ext variants using mass spectroscopy is 
currently under extensive exploration in our lab. 
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The presence of the extra intramolecular disulfide bond(s) for hCD83ext produced by 
Origami B(DE3) mediated a slight shift in the composition of the secondary structure of 
hCD83ext from α-helix to β-sheet with a minimum influence on the composition of the 
unordered structure. While the local environment surrounding the two tryptophan residues in 
the two hCD83ext product variants appeared to be similar in terms of tryptophan exposure 
(λmax > 340 nm), the emission fluorescence was slightly red-shifted (Δλmax = 5 nm; implying 
a more polar local environment surrounding the two tryptophan residues) and significantly 
quenched for hCD83ext produced by Origami B(DE3). Emission quenching via disulfide 
bonds which acted as electron scavengers absorbing electrons from excited indole ring of 
tryptophan was previously reported [90]. Alternatively, the hCD83ext variant with an 
intramolecular disulfide bond(s) could possibly develop a conformation that facilitates the 
transfer of emission energy, resulting in the above quenching. Apparently, these 
conformational changes potentially associated with intramolecular disulfide bond formation 
enhanced the subsequent formation of intermolecular disulfide bond for dimerization, 
possibly by shifting the local environment and orientation of cysteine residues to facilitate 
their spatial contact. The results indirectly suggest that transient protein structure or even 
protein sequence likely correlate with the probability of having cysteine residues to appear 
within a contact range to form aberrant disulfide bonds. 
It was previously reported that hCD83ext should be stored under frozen conditions 
due to its intrinsic instability [7]. Though protein degradation was prevented at -20 °C, 
hCD83ext tended to form dimers or even multimers via intermolecular disulfide bonds [7]. 
The present results show that the rate of dimerization increased with temperature. In addition, 
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both monomers and dimers were rather stable at -20 °C, whereas dimers were less stable than 
monomers at room temperature. Apparently, prolonged incubation of hCD83ext at a 
relatively high temperature resulted in faster dimerization and subsequent degradation, which 
could be a major cause for the intrinsic instability. Nevertheless, the stability issue appeared 




Molecular Manipulation Associated with Disulfide Bond Formation 
to Enhance the Stability of Recombinant Therapeutic Protein 
The work in this chapter was accepted by Protein Expr. Purif., in press 
Authors: Lin Zhang, Murray Moo-Young, and C. Perry Chou 
6.1 Introduction 
A technical issue closely related to protein quality is disulfide bond formation. Because a 
disulfide bond is formed by crosslinking two cysteine residues transiently adjacent to each 
other, it is plausible to assume that the formation probability can be explicitly determined by 
protein three-dimensional (3D) structure or even intrinsically encoded by protein sequence. 
To ensure a consistent performance, the therapeutic protein molecule should be designed and 
produced with a constant disulfide pattern. Manipulating cysteine residues within a given 
protein sequence becomes a rational strategy to either introduce desired disulfide bonds or 
prevent aberrant disulfide bonds which are often undesired. Because disulfide bond 
formation can potentially affect protein stability [45, 46, 91], the above cysteine 
manipulation strategy can have implications on protein stabilization [43, 92-98]. 
The therapeutic product hCD83ext produced using the developed bioprocess was 
subject to proteolysis, particularly during a prolonged storage (unpublished data). Structural 
monitoring of the therapeutic product suggested these cysteine residues were involved in 
forming aberrant (intramolecular and/or intermolecular) disulfide bonds under oxidative 
 
  83
storage conditions [7]. Formation of aberrant disulfide bonds was thus assumed to be 
associated with protein instability. To address this issue, we explored the derivation of 
mutant variants with enhanced stability by manipulating cysteine residues.  
Through conserved domain analysis in this study, Cys27 was identified as a key residue 
potentially involved in aberrant disulfide bond formation and, therefore, was designated as 
the target for mutagenesis. Two amino acids were selected to replace Cys27, i.e. glutamic acid 
which results in the highest statistic significance of homology to conserved domain families 
and serine which is a common substitution for cysteine. Two E. coli B strains, i.e. BL21 and 
Origami B with a reductive and oxidative cytoplasm, respectively, were used to express the 
mutant proteins since significantly different molecular properties were observed for the wild-
type hCD83ext expressed in these two strains [99]. The mutant proteins were produced using 
the previously developed bioprocess [7] for structural monitoring and characterization. 
 
6.2 Materials and Methods 
6.2.1 Conserved Domain Search and Structural Prediction of hCD83ext 
Conserved domain search was performed against the Conserved Domain Database (CDD; 
http://www.ncbi.nlm.nih.gov/cdd) using the default parameters. The 3D structure of 
hCD83ext was predicted using RAPTOR (Bioinformatics Solutions, Waterloo, Ontario, 
Canada), a bioinformatics software for predicting protein structures through protein threading 
[100]. The A chain of rat myelin oligodendrocyte glycoprotein (PDB code: 1pkoA) was 
identified as the best template for modeling.  
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6.2.2 Bacterial Strains and Construction of hCD83ext Mutants 
Plasmid pGEX2ThCD83ext contains the wild-type hCD83ext cDNA fused with the gst gene 
[8]. The two plasmid derivatives constructed in this study, i.e. 
pGEX2ThCD83ext_mut_C27E and pGEX2ThCD83ext_mut_C27S, were used for the 
production of hCD83ext_mut_C27E and hCD83ext_mut_C27S. To construct these two 
plasmids, site-directed mutagenesis was performed using the QuikChange® Multi Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) with pGEX2ThCD83ext as the 
template. Two primers of 5'-GAGGTGAAGGTGGCGAGCTCCGAAGATGTG-3' and 5'-
CCGGAGGTGAAGGTGGCTGAGTCCGAAGATGTGGAC-3' were used to replace 
Cysteine27 with serine and glutamic acid, respectively (Note: Mutations are in italics and the 
codons corresponding to serine and glutamic acid are in bold). The primer containing the 
Cys27Ser mutation has a silent mutation generating an extra SacI restriction site and the 
primer containing the Cys27E mutation has a silent mutation generating an extra PleI 
restriction site (underlined). Purification of plasmid DNA was performed using a spin-
column kit (QIAGEN, Mississauga, Ontario, Canada). Mutations were verified by DNA 
sequencing. BL21(DE3)pLysS and its trxB and gor double mutant derivative Origami 
B(DE3)pLysS (EMD Biosciences/Novagen, La Jolla, CA, USA) were used as the expression 
hosts. Plasmid transformation was carried out by electroporation.  
6.2.3 Protein Production and Purification 
The production and purification of hCD83ext variants, i.e. wild-type hCD83ext, 
hCD83ext_mut_C27S and hCD83ext_mut_C27E, in the two host strains was performed 
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using the bioprocess developed previously [7]. The protein products were formulated in 50% 
glycerol. 
6.2.4 Analytical Methods 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed in a 
Mini-PROTEAN®II electrophoresis cell (Bio-Rad, Hercules, CA, USA) under both reducing 
and non-reducing conditions using a 12.5% polyacrylamide separating gel stacked by a 4% 
polyacrylamide stacking gel. Reduced and non-reduced protein samples were prepared using 
the 2X sample buffer [65 mM Tris-HCl, pH6.8, 25% glycerol, 2% (w/v) SDS, 0.01% (w/v) 
bromophenol blue] respectively supplemented with 5% 2-mercaptoethanol and 10 mM N-
ethylmaleimide (NEM). Electrophoresis was conducted at a constant voltage of 200 V for 
approximately 50 min. The gel was stained with silver nitrate, dried, and then scanned for 
documentation.  
Protein samples at 0.1 mg/mL were prepared in 20 mM Tris-HCl buffer (pH 7.0) for 
spectroscopic analysis. Circular dichroism (CD) spectra were obtained using a 
spectropolarizer (J-810; Jasco, Tokyo, Japan). A cuvette with a path length of 0.1 cm was 
used for measurement in the far ultraviolet (UV) region from 250 to 190 nm. Fluorescence 
spectra were obtained using a spectrofluorometer (FP-6500; Jasco). A cuvette with a path 
length of 1 cm was used for fluorescent measurement in the range of 300~420 nm at an 
excitation wavelength of 295 nm. All spectra were recorded at ambient temperature. The 
average of three scans were taken and corrected by subtracting the buffer spectrum obtained 
under the same conditions. 
 
  86
To conduct the analysis using reversed-phase high performance liquid 
chromatography (rp-HPLC), 20 μL of the purified protein product was acidified by adding 1 
µL 4% TFA and then injected to ÄKTApurifier™ 10  (GE Healthcare, Baie d'Urfé, Québec, 
Canada) equipped with a C8 column (ACE 222-2546, 5 µm particle size, 300 Å pore, 4.6 
mm × 250 mm; Mac-Mod, Chadds Ford, PA, USA) for separation and a zinc lamp for UV 
detection at 214 nm. This separation was performed through a linear gradient elution of 30 to 
40% solvent B over the course of 25min at a flow rate of 0.7 mL/min [Solvent A: 0.1% 
trifluoroacetic acid (TFA) in water; solvent B: 0.1% TFA in acetonitrile (ACN)].  
 
6.3 Results 
6.3.1 Identification of the Key Cysteine Residue for Manipulation  
The results of the conserved domain search, including the length of the conserved domains, 
the significance of similarity (E-value), and the sequence alignment, are documented in 
Figure 6.1A. The local sequence, i.e. hCD83ext, was found to have a high structural 
similarity to the immunoglobulin (Ig) domain superfamily, especially the Ig variable-set (V-
set) domain. Note that there is a 15-AA difference between the cloned hCD83ext sequence 
number in Figure 6.1A and the actual hCD83ext sequence number (adopted elsewhere in this 
paper) because of the lack of the 19-AA signal peptide and the additional 4 AAs resulting 
from the design of a thrombin cleavage site joining GST and hCD83ext. Two cysteine 
residues in hCD83ext, i.e. Cys35 and Cys107 (boxed and in red), are conserved, whereas 
Cys27and Cys100 are non-conserved (in blue). Cys129 is not located in the conserved domain. 
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The predicted 3D protein structure of hCD83ext with labeled cysteine residues was shown in 
Figure 6.1B. The two cysteine pairs, i.e. Cys35/Cys107 and Cys27/Cys100, were spatially close 
within a β-sheet, whereas Cys129 was relatively distant from the other cysteines. An 
intramolecular disulfide bond between Cys35 and Cys107 was previously predicted [9]. 
Recently, we observed that several free cysteines in hCD83ext can be involved in thiol-
disulfide exchange known as disulfide scrambling [101], implying that the presence of free 
cysteines can possibly jeopardize the structural consistency. In that regard, the presence of 
Cys27 might be unfavorable and, therefore, was selected as the target for mutagenesis. The 
substituted AA was selected on the basis of the sequence homology to the Ig domain family 
and V-set domain. The calculated E-values for all Cys27 substitutions are summarized in 
Table 6.1. Noticeably, C27E had the highest homology to both conserved domains. In 
addition, C27S was selected since serine is a common AA substitution for cysteine. 
6.3.2 Bacterial Cultivation for Mutant hCD83ext Expression 
Using BL21(DE3)pLysS and Origami B(DE3)pLysS as the host, cultivation for the 
expression of GST-hCD83ext_mut_C27E and GST-hCD83ext_mut_C27S was conducted in 
a bench-top bioreactor and the results are summarized in Figures 6.2 and 6.3. While there is 
no significant host effect on the expression level, the growth rate and biomass yield of 
recombinant Origami B(DE3) was approximately 30% lower than that of recombinant 
BL21(DE3). In addition, approximately 50% of the GST-hCD83ext fusion was expressed 
insolubly in both hosts. Interestingly, the electrophoretic mobility of the GST-hCD83ext 
fusion expressed in BL21(DE3) was approximately the same as that expressed in Origami 
















Figure 6.1 Conserved domain analysis in hCD83ext sequence performed by NCBI CD-search 
BLAST. (A) Pairwise alignments between the hCD83ext sequence (displayed as local) and 
the domain-model consensus sequences from Immunoglobulin domain family (the upper 
panel) and Immunoglobulin V-set domain (the lower panel). The conserved cysteine residues 
were boxed and the cysteine at the position 27 in hCD83ext was marked with black heart. 
SMART and Pfam are imported collections as the sources of conserved domain-search 
alignment model data [2]. Smart00409 and Pfam07686 were identified as the domain-models 
for hCD83ext sequence. (B) Predicted 3D structure of hCD83ext (shown in backbone style). 
The positions of five cysteine residues were marked as pointed by arrows. 
CD length:86 Bit Score:36.65 E-value:0.002
10        20        30        40        50        60        70 80
....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
local        6 PEVKVACSEDVDLPCTAPWDPqvPYTVSWVKlleggeermeTPQEDHLRGQHYHQKGQNGSFdapnerpySLKIRNTISC 85
smart00409   2 PSVTVKEGESVTLSCEASGNP--PPEVTWYK----------QGGKLLAYSGRFSVSRSGGNS--------TLTISNVIPE 61
90       100
....*....|....*....|....*..
local       86 NSGTYRCTLQDPDDQrnLSGKVILRVT 112
smart00409  62 DSGTYICAATNSSGS--ASSGTTLTVL 86
CD length:115 Bit Score:40.26 E-value:1e-04
10        20        30        40        50        60        70  80
....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
local        5 TPEVKVACSEDVDLPCTaPWDPQVPYTVSWVKLLEG-GEERMETPQEDHLRGQHYHQKGQNGSFDA-PNERPYSLKIRNT 82
pfam07686    8 PRPVTVAEGGSVTLPCT-YSSSSGSTSVYWYRQPTGkGPELIIHYVTSTNNGKVGPRFSGRVTLSGnGSKNDFSLTISNL 86
90       100       110
....*....|....*....|....*....|
local       83 TSCNSGTYRCTLQDPDGQRNLSGkVILRVT 112

















Figure 6.1 (Continued) 
 
 
vo formation of intramolecular disulfide bond in Origami B(DE3) was rather ineffective. The 
observation is distinct from that when the fusion of GST and wild-type hCD83ext was 






Table 6.1 E-values (expectation values) corresponding to the substitution of cysteine 27 with 
the other 19 amino acids (AAs). The E-value is used to compare the similarity of a query 


























AA Ig family V-set domain 
C 0.002 1e-04 
G 0.001 7e-05 
A 4e-04 3e-05 
V 4e-04 1e-05 
L 4e-04 1e-05 
I 5e-04 2e-05 
M 6e-04 2e-05 
F 0.002 4e-05 
W 0.003 8e-05 
P 2e-04 1e-05 
S 7e-04 3e-05 
T 0.001 2e-05 
Y 0.002 7e-05 
N 0.001 2e-05 
Q 5e-04 2e-05 
D 7e-04 3e-05 
E 2e-04 6e-06 
K 7e-04 3e-05 
R 5e-04 1e-05 












Figure 6.2 Comparison of bioreactor cultivation performance for the production of GST-
hCD83ext_mut_C27E in two host strains: Cell density (Panel A), specific GST activity 
(Panel B), and intracellular protein analysis of both soluble and insoluble fractions under 
reducing and non-reducing conditions with SDS-PAGE (Panel C) and Western blotting 
(Panel D) for the culture samples taken prior to induction and at 6 h post-induction time were 
shown. Panel C: Lane 1 is molecular weight marker; Lanes 2, 3, 10, 11 and 4, 5 represent 
soluble and insoluble fractions of samples produced by BL21(DE3)pLysS, respectively, 
whereas lanes 6, 7, 12, 13 and 8, 9 represent soluble and insoluble fractions of samples 
produced by Origami B(DE3)pLysS, respectively. Arrows represent the protein bands 
corresponding to monomeric fusion protein. Panel D: All lanes are corresponding to the lanes 
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Figure 6.3 Comparison of bioreactor cultivation performance for the production of GST-
hCD83ext_mut_C27S in two host strains: Cell density (Panel A), specific GST activity 
(Panel B), and intracellular protein analysis of both soluble and insoluble fractions under 
reducing and non-reducing conditions with SDS-PAGE (Panel C) and Western blotting 
(Panel D) for the culture samples taken prior to induction and at 6 h post-induction time were 
shown. Panel C: Lane 1 is molecular weight marker; Lanes 2, 3, 10, 11 and 4, 5 represent 
soluble and insoluble fractions of samples produced by BL21(DE3)pLysS, respectively, 
whereas lanes 6, 7, 12, 13 and 8, 9 represent soluble and insoluble fractions of samples 
produced by Origami B(DE3)pLysS, respectively. Arrows represent the protein bands 
corresponding to monomeric fusion protein. Panel D: All lanes are corresponding to the lanes 











































































Figure 6.3 (Continued) 
 
 
6.3.3 Characterization of Multimerization  
Structural monitoring of the four hCD83ext mutant variants was conducted under -20 °C and 





























Figure 6.4 Monitoring and comparison of multimerization for hCD83ext_mut_C27E 
produced by two host strains with reducing SDS-PAGE (Panels A and C), non-reducing 
SDS-PAGE (Panels B and D): Samples up to 30-day storage at -20 °C and room temperature 
were analyzed. Panels A and B represent hCD83ext_mut_C27S samples produced by 
BL21(DE3)pLysS, whereas Panels C and D represent hCD83ext_mut_C27E samples 
produced by Origami B(DE3)pLysS. Panels A~B: lane 1/ molecular weight markers; lane2/ 
day 0; lanes 3 ~ 7/ -20 °C samples taken on day 1, day 2, day 6, day 10, and day 30, 
respectively; lanes 7 ~ 10/ room temperature samples taken on day 1, day 2, day 6, day 10, 
and day30 respectively. Panels C~D: lane 1/ molecular weight markers; lane2/ day 0; lanes 3 
~7/ -20 °C samples taken on day 1, day 2, day 6, day 10, and day 30, respectively; lanes 
8~10/ room temperature samples taken on day 1, day 2, and day 6 respectively. The insets at 
upper right in Panels B and D represent the time profiles for dimerization of 
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Figure 6.5 Monitoring and comparison of multimerization for hCD83ext_mut_C27S 
produced by two host strains with reducing SDS-PAGE (Panels A and C) and non-reducing 
SDS-PAGE (Panels B and D): Samples up to 30-day storage at -20 °C and room temperature 
were analyzed. Panels A and B represent hCD83ext_mut_C27S samples produced by 
BL21(DE3)pLysS, whereas Panels C and D represent hCD83ext_mut_C27S samples 
produced by Origami B(DE3)pLysS. Panels A~B: lane 1/ molecular weight markers; lane2/ 
day 0; lanes 3 ~7/ -20 °C samples taken on day 1, day 3, day 5, day 10, and day 30, 
respectively; lanes 8~12/ room temperature samples taken on day 1, day 3, day 5, day 10, and 
day30 respectively. Panels C~D: lane 1/ molecular weight markers; lane2/ day 0; lanes 3 ~6/ 
-20 °C samples taken on day 2, day 5, day 10, and day 30, respectively; lanes 7~10/ room 
temperature samples taken on day 2, day 5, day 10, and day30 respectively. The insets at 
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hCD83ext_mut_C27S stored at -20 °C and room temperature. Multimerization profiles were 
further plotted according to the relative abundance of monomeric and multimeric forms 

















































































1          2       3        4        5         6          7 8         9        10
C





























-20 °C room temperature
 
  101
Monomeric and multimeric forms of hCD83ext were quantified by scanning the band 
intensity and various time profiles of multimerization were obtained. Kinetic simulation was 
conducted with an assumption that dimerization occurred exclusively since dimer represents 
the majority of multimeric forms. The two kinetic parameters, i.e. reaction order and rate 
constant, were estimated using the Metropolis-Hastings algorithm [102]. The reaction orders 
based on the eight scenarios in Figures 6.4 and 6.5 were determined to be 1.9~2.6. Therefore, 
a second-order reaction kinetics was used for data fitting to obtain rate constants (Table 6.2). 
Apparently, the multimerization was enhanced by an elevated temperature for all mutant 
variants. The hCD83ext mutant variants with a serine substitution or produced by Origami 
B(DE3) had a higher tendency for multimerization as compared to those counterparts with a 
glutamic acid substitution or produced by BL21(DE3).  
6.3.4 Characterization of Conformational Changes  
We also used rp-HPLC to characterize the change in protein surface hydrophobicity and the 
chromatograms of protein products stored at -20 °C are documented in Figure 6.6. Several 
peaks eluted at approximately 32.8%, 33.6%, 34.1% and 34.5% ACN were identified as 
structurally distinctive forms, implying that all mutant variants experienced structural 
changes. They all tended to come into the conformation with more surface hydrophobicity 
associated with the storage. The structural changes in the Origami-derived proteins appear to 
be more significant as compared to the BL21(DE3)-derived counterparts, presumably due to 
their enhanced tendency for multimerization. We also monitored the number of titratable free 
sulfhydryl group using Ellman’s assay [35] (data not shown). In general, the number for all 
protein samples decreased monotonically, implying that disulfide bonds formed in vitro duri- 
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R2 R2 –critical 
hCD83ext_mut_C27S 
from BL21(DE3)pLysS at -20 °C 3.04 × 10
-3 0.9011 0.6583 
(N=6) 
hCD83ext_mut_C27S 
from BL21(DE3)pLysS at RT 1.33 × 10
-1 0.9675 0.6583 
(N=6) 
hCD83ext_mut_C27S 
from Origami B(DE3)pLysS at -20 °C 7.25 × 10
-2 0.9933 0.7714 
(N=5) 
hCD83ext_mut_C27S 
from Origami B(DE3)pLysS at RT 5.45 × 10
-1 0.9954 0.7714 
(N=5) 
hCD83ext_mut_C27E 
from BL21(DE3)pLysS at -20 °C 2.62 × 10
-3 0.799 0.6583 
(N=6) 
hCD83ext_mut_C27E 
from BL21(DE3)pLysS at RT 8.80 × 10
-2 0.9811 0.6583 
(N=6) 
hCD83ext_mut_C27E 
from Origami B(DE3)pLysS at -20 °C 2.21 × 10
-2 0.9234 0.6583 
(N=6) 
hCD83ext_mut_C27E 
from Origami B(DE3)pLysS at RT 3.39 × 10
-1 0.9969 0.9025 
(N=4) 
 
N is the number of independent sample measurements. The goodness of fit was checked by 
coefficient R2 using R2-critical calculated through critical values of the Student’s t-distribution with 




ng the storage. The disulfide bond formation was aggravated by an elevated temperature, 
particularly in the initial incubation. Spectroscopic analysis of the conformational change 
was conducted using far-UV CD and fluorescence spectroscopy. Based on the deconvolution 
of far-UV CD spectra using the CDSSTR method on DichroWeb website [103, 104], it 
appears that no hCD83ext mutant variant had a major change in the secondary structure other 
than a slight increase in β-sheets (1~4%). However, overlaying far-UV CD spectra with 
different ages suggests otherwise, particularly in light of the signal differences at 195, 203 
and 220 nm wavelengths which are typically associated with β-sheets. The Origami-derived 
proteins had more variations at 220 nm, whereas the BL21-derived counterparts displayed 
blue-shifts at shorter wavelengths. In the meantime, Origami-derived proteins had a 
significantly lower fluorescence intensity as compared to the BL21(DE3)-derived 
counterparts, suggesting the formation of certain intramolecular disulfide bond(s) could 
result in a major structural change in the local environment surrounding tryptophan residues. 
However, no specific pattern of fluorescence change associated with storage was observed.  
6.3.5 Stability Enhancement Associated with the Cys27 Mutations 
The changes in molecular structure for the wild-type hCD83ext and two Cys27 mutants upon 
a long-term storage at -20 °C and a room temperature was monitored and the results are 
summarized in Figure 6.7. Wild-type hCD83ext were stable at -20 °C, but subject to 
degradation at a room temperature. The degradation was significantly alleviated for the two 
Cys27 mutants. Interestingly, the trend of multimerization for hCD83ext variants was affected 






















Figure 6.6 Monitoring and comparison of the retention behavior of hCD83ext mutant 
variants in rp-HPLC:  Panels A and C represent hCD83ext_mut_C27E produced by 
BL21(DE3)pLysS and samples were taken at day 0 and day 30 under -20 °C storage, 
respectively; Panels B and D represent hCD83ext_mut_C27E produced by Origami 
B(DE3)pLysS and samples were taken at day 0 and day 30 under -20 °C storage, 
respectively. Panels E and G represent hCD83ext_mut_C27S produced by BL21(DE3)pLysS 
and samples were taken at day 0 and day 30 under -20 °C storage, respectively; Panels F and 
H represent hCD83ext_mut_C27S produced by Origami B(DE3)pLysS and samples were 





























































































































Figure 6.6 (Continued) 
 
 
Compared to wild-type hCD83ext stored at -20 °C, the two Cys27 mutants derived from 
BL21(DE3) showed a lower tendency for dimerization (lanes 4 and 6 vs. lane 2). However, 
using Origami B(DE3) as the expression host increased the dimerization (Lane 5 vs. lane 4 
and lane 7 vs. lane 6). The dimerization enhancement associated with the Cys27 mutations 
and the use of Origami B(DE3) as the expression host can be clearly observed for hCD83ext 













































































































increased dimerization (lanes 11 and 12 for hCD83ext_mut_C27E) or even multimerization 
(lanes 13 and 14 for hCD83ext_mut_C27S), which could prevent the degradation and 
subsequently enhanced the structural stability. The electrophoretic mobility of the non-
reduced mutant monomers (18 kDa) or dimers (30 kDa) was higher than that of the 
corresponding non-reduced wild-type monomers (15 kDa) or dimers (27 kDa) (Figure 7B). 
The difference in the electro-mobility is presumably associated with the intramolecular 
disulfide bonding patterns and/or the number of intramolecular disulfide bonds. The stability 
enhancement was supported by spectroscopic analyses with far-UV CD and fluorescence. 
The CD spectra associated with the two storage temperatures for the wild-type hCD83ext had 
major differences, such as different signals at 203 nm and different band patterns at 195 nm, 
whereas these differences were insignificant for the two Cys27 mutants. In particular, the red-
shift at 220 nm wavelength, which was previously suggested to be associated with the 
degradation for the Origami-derived wild-type sample at a room temperature [105], was not 
observed for the two Cys27 mutants. The signal variations within the 203~220 nm range of 
the far-UV CD spectra suggest that the β-sheet structure of hCD83ext might be twisted rather 
than planar [82], which is very common in globular proteins [106, 107]. The twist was 
suggested to affect the stability of the β-sheet structure through mediating the burial of 
hydrophobic surfaces [108] and, therefore, might have implications in the structural stability 
of hCD83ext which has more than 60% β-sheet structure (i.e. β-strands and β-turn). 
Similarly, the fluorescence spectra associated with the two storage temperatures for the wild-
type hCD83ext were rather distinguishable, such as the increased signal at 400~420 nm and 
major red-shift of the emission maximum for room-temperature samples. The fluorescence 
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emission maximum at ~350 nm suggests that tryptophan residues are located on the protein 
surface in contact with free water molecules [109], whereas the oxidized forms of tryptophan 
emit fluorescence at distinctively longer wavelengths (400~420 nm) [110]. This features 
associated with the structural instability [105] were not observed for the two Cys27 mutants. 
 
6.4 Discussion 
The presence of free cysteines within a protein molecule can possibly lead to the aberrant 
formation of disulfide bonds in an oxidative storage condition. These cysteines become a 
rational target for molecular manipulation. On the other hand, a fixed disulfide pattern is 
presumably critical for developing consistent bioactivity for protein therapeutics. As a result, 
bioprocessing strategies leading to the desired disulfide pattern can play a pivotal role to 
ensure the quality of biopharmaceuticals. For example, controlling the oxidative state of a 
protein solution has been adopted to regulate the in vitro formation of disulfide bonds [111]. 
However, it is generally believed disulfide bond formation can be more consistently 
mediated in vivo (i.e. in biological cells) even though the desired disulfide pattern might not 
necessarily be developed. Since Origami B(DE3) is genetically manipulated to transform its 
cytoplasm into an oxidative compartment allowing disulfide bond formation [11, 73], the 
strain was applied to express the two Cys27 mutants of hCD83ext in this study. As opposed to 
the expression of wild-type hCD83ext in Origami B(DE3) where intramolecular disulfide 
bonds formed in vivo [99], the efficiency of disulfide bond formation was significantly 
reduced when the two Cys27 mutants were expressed in Origami B(DE3) (Figures 2 and 3). 
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The results suggest that Cys27 might be involved in the formation of intramolecular disulfide 











Figure 6.7 Monitoring and comparing the stability of hCD83ext wild-type protein with 
mutant proteins hCD83ext_mut_C27E and hCD83ext_mut_C27S produced by two host 
strains by reducing SDS-PAGE (Panel A), non-reducing SDS-PAGE (Panel B), CD 
spectroscopy (Panels C, D, and E), and fluorescence spectroscopy (Panels E, F, and G). 
Samples up to 30-day storage at -20 °C and room temperature were analyzed except that 
hCD83ext_mut_C27E produced in Origami B(DE3)pLysS was monitored till 6-day when 
stored at room temperature. Panels A and B : lane 1/ molecular weight markers; lanes 2~7/ -
20 °C samples, arranged as lane 2/ wild-type from BL21(DE3)pLysS, lane 3/ wild-type from 
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hCD83ext_mut_C27E from Origami B(DE3)pLysS, lane 6/ hCD83ext_mut_C27S from 
BL21(DE3)pLysS, lane 7/ hCD83ext_mut_C27S from Origami B(DE3)pLysS; lane 8/ wild-
type from Origami B(DE3)pLysS 6-day storage at RT; lanes 9~14/ corresponding RT 
samples following the same arrangement. The arrows indicate the monomeric and dimeric 
species of different mobilities in wild-type and mutant proteins. Due to the limited amount of 
the sample, hCD83ext_mut_C27E produced by Origami B(DE3)pLysS was monitored for 6 
days at room temperature. Accordingly, the comparison was made to the wild-type hCD83ext 



































































































































































































In addition to the in vivo effect, the Cys27 mutations significantly affected the in vitro 
molecular behavior of the protein product during the storage. Similar to wild-type hCD83ext 
[99], multimerization via the in vitro formation of intermolecular disulfide bonds still 
occurred to the two Cys27 mutants derived from either BL21(DE3) or Origami B(DE3). The 
Origami-derived Cys27 mutant variants had a higher tendency for multimerization than the 
BL21-derived counterparts and certain structural variations in the fresh protein products 
could be associated with this different multimerization behavior. However, such structural 
variations are expected to be less significant than those associated with the fresh protein 
products of wild-type hCD83ext derived from BL21(DE3) and Origami B(DE3) [99] based 
on at least two observations. First, the efficiency for the in vivo formation of intramolecular 
disulfide bonds in Origami B(DE3) was seriously impaired by the Cys27 mutations (Figures 
6.2 and 6.3). Second, the analysis based on the fluorescence spectroscopy (i.e. quenching of 
the tryptophan fluorescence reflected by the different intensity at the emission maximum) 
revealed fewer conformational differences between the Cys27 mutants derived from 
BL21(DE3) and Origami B(DE3), as compared to the case of wild-type hCD83ext [99]. Note 
that the electrophoretic mobility of the monomer of the Origami-derived products was 
approximately the same as that of the BL21-drived counterparts. Because the intramolecular 
disulfide bonds cannot be formed in the reducing cytoplasm of BL21(DE3), the results imply 
they are effectively formed in vitro during the downstream processing (unpublished data). 
The in vitro multimerization of the Cys27 mutant also appears to be aggravated more by Ser 
substitution than Glu substitution (for both BL21-derived and Origami-derived products) and 
this could be due to increased steric hindrance and impulsion associated with the bulky and 
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negatively charged side chain of glutamic acid. The argument is supported by the 3D 
structural prediction that Cys27 is lies in a turn connecting two β-strands near the surface. 
Molecular stability of protein therapeutics has been recognized as a key issue in 
biopharmaceutical research and development since denatured and instable proteins can 
potentially jeopardize the safety and efficacy of therapeutic products [30]. Recombinant 
hCD83ext has been found to be susceptible to degradation during a prolonged storage 
particularly at elevated temperatures [105]. In this study, molecular stability of hCD83ext 
was found to be enhanced by the Cys27 mutations with a concomitantly altered disulfide 
pattern. Based on the reduced electrophoretic mobility, the Cys27 mutant variants could have 
less intramolecular disulfide bonds in average, compared to that of the wild-type hCD83ext 
[35]. This argument is supported by the Ellman assay results that more titratable free 
sulfhydryl groups are presented in the Cys27 mutant variants. Therefore, mutating Cys27 
might somehow prevent the formation of intramolecular disulfide bond, both in vivo and in 
vitro, and this preventing effect was independent of the expression host. The stability 
improvement associated with the Cys27 mutations appears to be mediated through 
multimerization since all multimeric forms of the Cys27 mutants were much less susceptible 
to degradation. On the other hand, the multimerization did not improve the molecular 
stability for wild-type hCD83ext, suggesting the presence of structural variations between the 
Cys27 mutant and wild-type hCD83ext. The results also suggest that Cys27 might not be 
critically involved in the formation of intermolecular disulfide bonds for multimerization. 
Recently, we have identified Cys100 as a key cysteine responsible for multimerization [101], 
implying that the sulfhydryl group of Cys100 should be retained in monomeric hCD83ext 
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prior to multimerization. Based on the predicted 3D structure of hCD83ext (Figure 6.1B), 
Cys27 is spatially close to both Cys100 and Cys129, suggesting possible formation of 
intramolecular disulfide bonds among these cysteine residues. In particular, the formation of 
an intramolecular disulfide bond between Cys27 and Cys100 could inactivate multimerization. 
This argument is supported by the observation that multimerization was enhanced upon 
introducing the Cys27 mutation, which can potentially free more Cys100 sulfhydryl groups for 
multimerization. Though molecular stability was improved upon introducing the Cys27 
mutations, consistent bioactivity tends to be affected by the aggravated multimerization 




Identification of Molecular Roles of Cysteine Residues Associated 
with In Vitro Multimerization of Therapeutic Protein Human CD83 
7.1 Introduction 
An hCD83ext mutant (i.e. M3) with a Cys100Ser mutation was derived to exhibit a more 
consistent bioactivity without disulfide-driven multimerization [101]. The underlying 
mechanisms associated with the improvement in molecular property and therapeutic 
bioactivity for M3 remained uncharacterized. In this study, more extended mutants of M3, 
i.e. M13 (Cys27Ser/Cys100Ser), M135 (Cys27Ser/Cys100Ser/Cys129Ser) and M35 
(Cys100Ser/Cys129Ser), were derived and two E. coli B strains, i.e. BL21 and Origami B, 
were used as the expression host to produce these mutant derivatives. The molecular 
structures of these hCD83ext mutant variants were characterized and compared. The 
characterization data enable us to gain a partial insight regarding the structural role that these 





7.2 Materials and Methods 
7.2.1 Bacterial Strains and Construction of hCD83ext Mutants 
Plasmid pGEX2ThCD83ext contains the wild-type hCD83ext cDNA fused with the gst gene 
[8]. The two plasmid derivatives of pGEX2ThCD83ext_mut_C100S and 
pGEX2ThCD83ext_mut_C27S/C100S were used to produce hCD83ext_mut_C100S (i.e. 
M3) and hCD83ext_mut_C27S/C100S (i.e. M13). To construct these plasmids, site-directed 
mutagenesis was performed using QuikChange® Multi Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, USA) with pGEX2ThCD83ext as the template. Two primers of 5'-
ATCCGAAACACTACGAGCTCCAACTCGGGG-3' for mutating Cys residue at the 
position AA100 to Ser and 5'-GAGGTGAAGGTGGCGAGCTCCGAAGATGTG-3' for 
mutating Cys residue at the position AA27 to Ser (nucleotidic mutations are denoted in italics 
and the codons corresponding to serine are in bold). Both primers have a silent mutation 
generating an extra SacI restriction site (underlined). By using the same primers with the 
PCR template of pGEX2ThCD83ext_mut_C129S (kindly presented by Prof. Lechmann), two 
plasmid derivatives pGEX2ThCD83ext_mut_C100S/C129S and 
pGEX2ThCD83ext_mut_C27S/C100S/C129S were constructed and used for the production 
of hCD83ext_mut_C100S/C129S (i. e. M35) and hCD83ext_mut_C27S/C100S/C129S (i.e. 
M135). Purification of plasmid DNA was performed using a spin-column kit (QIAGEN, 
Mississauga, Ontario, Canada). The correct nucleotide sequences were verified by 
sequencing. BL21(DE3)pLysS and its trxB and gor double mutant derivative Origami 
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B(DE3)pLysS (EMD Biosciences/Novagen, La Jolla, CA, USA) were used as the expression 
hosts. Plasmid transformation was carried out by electroporation. 
7.2.2 Protein Production and Purification 
The production and purification of hCD83ext mutant variants, i.e. M3, M13, M35 and M135, 
in the two host strains was performed using the bioprocess developed previously [7]. The 
protein products were formulated in 50% glycerol. 
7.2.3 Sample Treatment for Analyses 
The culture sample was appropriately diluted with saline solution for measuring cell density 
at OD600 with a spectrophotometer (DU®520, Beckman Coulter, Fullerton, CA, USA). For 
the preparation of cell extract, cells in the amount of 20 OD600-units (defined as ‘OD600×mL’) 
were centrifuged at 6000 × g and 4 °C for 10 min. The cell pellet was resuspended in 0.75 
mL phosphate-buffered saline (pH 7.3), sonicated intermittently (i.e. 0.5 s/0.5 s on/off) for 4 
min using an ultrasonic processor (Misonix, Farmingdale, NY, USA) with a microtip, and 
then centrifuged at 15,000 × g and 4 °C for 15 min to remove cell debris. The supernatant 
containing soluble proteins was used for sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting analyses. The pellet containing insoluble 
proteins and cell debris was washed with phosphate buffer, resuspended in TE/SDS buffer 
(10 mM Tris HCl, pH 8.0, 1 mM EDTA, 1% SDS), and heated to 100 °C for 5 min for 
dissolution. The protein content of the pellet was analyzed as the insoluble fraction. 
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7.2.4 Analytical Methods 
SDS-PAGE was performed in a Mini-PROTEAN®II electrophoresis cell (Bio-Rad, Hercules, 
CA, USA) under both reducing and non-reducing conditions using a 12.5% polyacrylamide 
separating gel stacked by a 4% polyacrylamide stacking gel. Reduced and non-reduced 
protein samples were prepared using the 2X SDS sample buffer [65 mM Tris-HCl, pH6.8, 
25% glycerol, 2% (w/v) SDS, 0.01% (w/v) bromophenol blue] respectively supplemented 
with 5% 2-mercaptoethanol and 10 mM N-ethylmaleimide (NEM). Electrophoresis was 
conducted at a constant voltage of 200 V for approximately 50 min. For the analysis of 
samples from cultivation, 0.0175 OD600-units of soluble and insoluble fractions were loaded 
and the gel was stained with Coomassie blue. For the monitoring of molecular properties 
during storage, 0.25 µg of protein was loaded and silver nitrate staining was applied for 
higher sensitivity. All gels were dried and scanned.  
To conduct Western blotting, the proteins on the polyacrylamide gel were 
electroblotted to a poly(vinylidene difluoride) (PVDF) membrane (Pall Life Sciences, 
Pensacola, FL, USA) after SDS-PAGE using a Mini Trans-Blot® Cell (Bio-Rad) according to 
a standard protocol [80]. The electrophoretic transfer was conducted at a constant voltage of 
100 V for 1 h. Protein-antibody binding was performed as described by Sambrook et al. [81]. 
The purified hCD83ext was used as an antigen for raising polyclonal anti-CD83 antibodies in 
rabbits. The secondary antibody was goat anti-rabbit IgG conjugated with horseradish 
peroxidase (Sigma-Aldrich, St. Louis, MO, USA). All hCD83-related polypeptides (GST-
hCD83ext mutant variants) were detected by a colorimetric method using 3,3’-
 
  119
diaminobenzidine tetrahydrochloride (DAB) as the substrate. The processed membrane was 
scanned. 
Protein samples at 0.1 mg/mL were prepared in 20 mM Tris-HCl buffer (pH 7.0) for 
spectroscopic analysis. Circular dichroism (CD) spectra were obtained using a 
spectropolarizer (J-810; Jasco, Tokyo, Japan). A cuvette with a path length of 0.1 cm was 
used for measurement in the far ultraviolet (UV) region from 250 to 190 nm. Fluorescence 
spectra were obtained using a spectrofluorometer (FP-6500; Jasco). A cuvette with a path 
length of 1 cm was used for fluorescence measurement in the range of 300~420 nm at an 
excitation wavelength of 295 nm. All spectra were recorded at an ambient temperature. The 




7.3.1 Rational for Mutagenesis Studies 
Because hCD83ext showed a high structural similarity to the Immunoglobulin V-set (IgV) 
domain [89], multiple sequence alignment between hCD83ext and several IgV members was 
conducted (Figure 7.1). Of the five cysteine residues in hCD83ext, Cys35 and Cys107 (boxed 
and in red) are highly conserved, whereas Cys27 and Cys100 (circled and in blue) are not. Note 
that Cys129 is not even included in the alignment. An intramolecular disulfide bond between 
Cys35 and Cys107 was previously predicted [9]. Because the presence of free cysteines can 
potentially result in the formation of aberrant disulfide bonds leading to inconsistent 
 
  120
molecular properties, Cys27, Cys100, and Cys129 were selected as the mutagenesis targets to 
eliminate possible free cysteines in hCD83ext in this study. In fact, the single mutation 
effects associated with each of these cysteines have been investigated [89, 101]. The 
combinatorial effects of these individual cysteine mutations and the expression host 
presented in this study enabled us to partially explore the underlying mechanism associated 












Figure 7.1 Multiple sequence alignment of the hCD83ext (query) with the other 
Immunoglobulin V-set domain members. The alignment was generated via NCBI Conserved 
Domain Search Blast on line. Conserved cysteine residues were boxed, whereas variable 
cysteine residues were circled in the hCD83ext sequence.  
 
  121
7.3.2 Comparison of Molecular Properties for M3 Variants 
Using BL21(DE3)pLysS and Origami B(DE3)pLysS as the hosts, cultivation for the 
expression of GST-hCD83ext_mut_C100S (M3) was conducted in a bench-top bioreactor 
and the results are summarized in Figure 7.2. The M3-GST fusion expressed in Origami 
B(DE3)pLysS had a higher electrophoretic mobility under a non-reducing condition 
compared to that of the corresponding monomeric form under a reducing condition (lane 7 
vs. 13), implying that certain intramolecular disulfide bond(s) was formed in the oxidative 
cytoplasm of Origami B(DE3). On the other hand, the same electrophoretic mobility for the 
M3-GST fusion expressed in BL21(DE3) under both reducing and non-reducing conditions 
(lane 3 vs. 11) suggested that no intramolecular disulfide bond was formed in BL21(DE3) 
host as expected.  
Structural analysis of two fresh M3 product samples was conducted using SDS-
PAGE, far-UV CD, and fluorescence spectroscopy, and the results are summarized in Figure 
7.3. Under a non-reducing condition, multimers, i.e. dimers and trimers formed presumably 
via intermolecular disulfide bonds, were distinctively present for the Origami B(DE3)-
derived M3 (Figure 7.3A). While BL21(DE3)-derived M3 had two disulfide bonded 
monomeric forms (i.e. two bands at 18 kDa and 15 kDa, Figure 7.3A), Origami B(DE3)-
derived M3 had one monomeric form (i.e. a band at 15 kDa, Figure 7.3A). Overlaying the 
far-UV CD and fluorescence spectra of the two M3 variants revealed significant structural 
differences at both secondary and tertiary levels. By comparing the far-UV CD spectra of the 
two variants (Figure 7.3B), the Origami B(DE3)-derived M3 showed more positive signals at 





















Figure 7.2 Intracellular protein analysis of both soluble and insoluble fractions under 
reducing and non-reducing conditions with SDS-PAGE (Panel A) and Western blotting 
(Panel B) for the culture samples of M3 taken prior to induction and at 6 h post-induction 
time were shown. Panels A & B: lane 1 was molecular weight markers; lanes 2, 3, 10, 11 and 
4, 5 represented soluble and insoluble fractions of samples produced by BL21(DE3)pLysS, 
respectively, whereas lanes 6, 7, 12, 13 and 8, 9 represented soluble and insoluble fractions 
of samples produced by Origami B(DE3)pLysS, respectively. Arrows in two panels indicated 
the protein bands corresponding to disulfide bonded and non-disulfide bonded monomeric 
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Figure 7.3 Structure analysis of fresh M3 (day-0 samples) produced by two host strains. 

































































they both displayed a β-sheet structure mixed with type II β-turn based on ~5 nm red-shift of 
all the featuring bands as compared to β-sheet CD spectra [82]. By comparing the tryptophan 
fluorescence spectra of the two variants (Figure 7.3C), the maximum emission intensity (at 
345 nm) of BL21(DE3)-derived M3 was approximately 4-fold that (at 350 nm) of Origami 
B(DE3)-derived M3 with a slight red-shift, suggesting that the formation of certain 
intramolecular and/or intermolecular disulfide bond(s) could result in a major conformational 
change in the local environment surrounding the tryptophan residues within M3.  
The molecular properties of the two M3 variants were compared by monitoring the 
conformational changes under storage conditions (either -20 °C or a room temperature) and 
the results are documented in Figure 7.4. While the two protein samples had an identical 
band pattern upon the analysis with reducing SDS-PAGE, they behaved rather distinctively 
in terms of disulfide bond formation upon the analysis with non-reducing SDS-PAGE. The 
monomeric doublet corresponding to BL21(DE3)-derived M3 merged into a single band with 
a higher electrophoretic mobility during the storage with no multimerization being observed. 
On the other hand, while the electrophoretic mobility of the monomeric form of Origami 
B(DE3)-derived M3 remained unchanged, significant multimerization was observed even at 
a frozen temperature of -20 °C presumably through the formation of intermolecular disulfide 
















Figure 7.4 Monitoring and comparison of molecular property for M3 produced by two host 
strains with SDS-PAGE: Samples up to 15-day storage at -20 °C and 10-day storage at room 
temperature were analyzed. Lane 1/ molecular weight markers; lanes 2, 5, 8, 11/ day 0; lanes 
3, 6, 9, 12/ -20 °C samples taken on day 15, lanes 4, 7, 10, 13/ room temperature samples 
taken on day 10. Arrows indicated protein bands corresponding to disulfide bonded 
multimeric forms.  
 
 
7.3.3 Comparison of Molecular Properties for Extended M3 Variants 
Molecular properties of the three extended M3 mutant variants, i.e. M13, M135 and M35, 
were characterized in a similar way to the above and the results are summarized in Figures 
7.5~7.8, respectively. While the M13-GST fusion expressed in Origami B(DE3)pLysS had 
an identical electrophoretic mobility under both reducing and non-reducing conditions (lane 

















7 vs. 13 in Panels A & B of Figure 7.5), the M135-GST and M35-GST fusions had a higher 
mobility under a non-reducing condition than those under a reducing condition (lane 7 vs. 13 
in Panels C & D and E & F of Figure 7.5), suggesting that certain intramolecular disulfide 
bond(s) was formed within the M135-GST and M35-GST fusions, but not the M13-GST 
fusion, upon their expression in Origami B(DE3). Note that the mobility increase for the 
Origami B(DE3)-derived M135-GST was less than that of Origami B(DE3)-derived M3-GST 
or M35-GST fusions, implying different intramolecular disulfide bond patterns existed in 
these fusions.  
There were two monomeric forms for M135 derived from BL21(DE3) (Figure 7.6B). 
Hence, the upper band with a mobility of 20 kDa represents the form with no disulfide bond 
and the lower band with a mobility of 18 kDa represents the form with a Cys35-Cys107 bridge 
which is the only possible disulfide bond that can be formed for M135. Since this disulfide 
bond cannot be formed in BL21(DE3), it must be formed in vitro during the downstream 
processing stage. On the other hand, there was only a single monomeric form with a mobility 
of 18 kDa, representing the form with the Cys35-Cys107 bridge, for M135 derived from 
Origami B(DE3). The enhanced efficiency in disulfide bond formation can be attributed to 
the in vivo oxidizing capacity of Origami B(DE3), which possibly mediated the formation of 
the Cys35-Cys107 bridge when M135-GST was expressed. Interestingly, no dimer was formed 
in BL21(DE3)-derived M135, whereas dimerization was somewhat observed for Origami 
B(DE3)-derived M135 (Figure 7.6B) and no progressive in vitro multimerization was 
observed during a prolonged storage (Figure 7.8B). The results suggest that neither Cys35 nor 
Cys107 was directly involved in the in vitro formation of intermolecular disulfide bonds for 
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multimerization. The M135 derived from the two hosts exhibited rather different 
spectroscopic profiles (Panels C and D of Figure 7.7). However, deconvolution of the CD 
spectra using the Contin method (DichroWeb: http://dichroweb.cryst.bbk.ac.uk/) only 
revealed a slight difference in the secondary structure composition of α-helix and β-sheet. 
The significant signal difference at short wavelengths of 195 nm and 203 nm (Figure 7.7C) 
can be associated with different levels of the splitting of the peptide ππ* transition and the 
twist of β-sheet [82]. Compared to BL21(DE3)-derived M135, the fluorescence intensity was 
significantly quenched for Origami B(DE3)-derived M135, presumably due to the presence 
of the Cys35-Cys107 disulfide bond which could act as an electron scavenger to absorb the 
electrons released from an excited indole ring of tryptophan [75, 90]. The results suggest that 
the significant changes in the spectroscopic profiles are primarily associated with the 
presence of the Cys35-Cys107 bridge.  
Dimers were observed for both M13 variants, but more abundant for the Origami 
B(DE3)-derived one (Figure 7.6A). Multimerization was significantly enhanced for M13 
compared to M135, implying the critical role that Cys129 played during the in vitro formation 
of intermolecular disulfide bonds for multimerization. Compared to M3 (Figure 7.4), M13 
appears to be less subject to degradation during the prolonged storage (Figure 7.8A) and the 
improved structural stability was associated with the Cys27 mutation and the aggravated trend 
for multimerization, particularly for Origami B(DE3)-derived M13. On the other hand, 
neither multimerization nor improved stability was observed for M35 (Figure 7.6C & 7.8C), 
supporting both the above arguments that the Cys129 was critically involved in the formation 
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of intermolecular disulfide bonds for multimerization and the Cys27 mutation could improve 

















Figure 7.5 Intracellular protein analysis of both soluble and insoluble fractions under 
reducing and non-reducing conditions with SDS-PAGE (Panels A, C, and E) and Western 
blotting (Panels B, D, and F) for the culture samples taken prior to induction and at 6 h post-




















M135, and M35, respectively. Panels A ~ D: lane 1 was molecular weight marker; Lanes 2, 
3, 10, 11 and 4, 5 represented soluble and insoluble fractions of samples produced by 
BL21(DE3)pLysS, respectively, whereas lanes 6, 7, 12, 13 and 8, 9 represented soluble and 
insoluble fractions of samples produced by Origami B(DE3)pLysS, respectively. Arrows in 
four panels indicated protein bands corresponding to disulfide bonded and non-disulfide 




























































































Figure 7.6 Structure analysis of fresh mutant variants produced by two host strains with SDS-




Recently, an hCD83ext mutant variant of M3 with the Cys100Ser mutation was identified to 
outperform the wild-type hCD83ext by exhibiting a consistent bioactivity. Structurally, no 
multimerization via the aberrant formation of intermolecular disulfide bonds was observed 
































































































































Figure 7.7 Structure analysis of fresh mutant variants produced by two host strains with CD 
spectroscopy (Panel A, C, and E) and fluorescence spectroscopy (Panel B, D, and F). Panels 

























































Figure 7.7 (Continued) 
 
 
In this study, multimerization was observed for the Origami B(DE3)-derived M3 mutant 
(Figure 3) as well as the M13 mutant derived from both BL21(DE3) and Origami B(DE3) 
(Figure 8A). The results suggest that Cys100 was not directly involved in the aberrant 
formation of intermolecular disulfide bonds for these mutant variants. We then propose that 
the Cys100 mutation might induce a major conformational change through which the in vitro 
multimerization was prevented. The preventing effect of such a conformational change on 
the multimerization could be suppressed by the presence of the Cys27 mutation or the 


































Figure 7.8 Monitoring and comparison of molecular property for mutant variants produced 
by two host strains with SDS-PAGE: samples up to 20-day storage at -20 °C and room 
temperature were analyzed. Panels A: M13, lane 1/ molecular weight markers; lanes 2, 5, 8 
and 11 / day 0; lanes 3, 6, 9 and 12 / -20 °C samples taken on day 20; lanes 4, 7, 10 and 13 / 
room temperature samples taken on day 20. Panel B: M135, lane 1/ molecular weight 
markers; lanes 2, 5, 8 and 11 / day 0; lanes 3, 6, 9 and 12 / -20 °C samples taken on day 20; 
lanes 4, 7, 10 and 13 / room temperature samples taken on day 20. Panel C: M35, lane 1/ 
molecular weight markers; lanes 2, 4, 6 and 8 / -20 °C samples taken on day 20; lanes 3, 5, 7 
and 9 / room temperature samples taken on day 20. Arrows indicated different multimeric 
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We also propose that Cys129 could be a primary cysteine residue directly involved in 
the formation of intermolecular disulfide bonds based on the following observations. First, 
the presence of the Cys27 mutation enhanced the multimerization (i.e. M13 vs. M3), 
precluding Cys27 from being the major bridging cysteine. This observation is also consistent 
to our previous results (i.e. M1 vs. wild-type hCD83ext) [89]. Second, no multimerization 
was observed for BL21(DE3)-derived M135 with the presence of two free cysteine residues 
of Cys35 and Cys107 (Figure 7.8B), precluding these two as the major bridging cysteine as 
well. Third, multimerization associated with M13, derived from either BL21(DE3) or 
Origami B(DE3), disappeared upon the introduction of the Cys129 mutation (i.e. M13 vs. 
M135). In fact, our current proposal that Cys129 could act as a primary bridging cysteine was 
previously reported based on an observation that no multimerization was observed for 
BL21(DE3)-derived M5 [9]. However, we recently reported a conflicting result, i.e. 
multimerization can still occur to BL21(DE3)-derived M5, based on a modified analytical 
protocol to prevent disulfide scrambling through which the intermolecular disulfide bonds 
could be broken [101]; suggesting that a cysteine residue(s) other than Cys129 can also act as 
the bridging cysteine for multimerization. With the above arguments precluding Cys27, Cys35, 
and Cys107 as the bridging cysteine, Cys100 appears to be another possible one. The 
conclusion is supported by the observation that multimerization associated with M5 was 
prevented by introducing the Cys100 mutation (i.e. M5 vs. M35). The overall results suggest 
that both Cys100 and Cys129 can possibly act as a bridging cysteine for in vitro 
multimerization and this conclusion is further supported by another two observations. First, 
no in vitro multimerization was observed for BL21(DE3)-derived or Origami B(DE3)-
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derived M35 (Figure 8C). Second, the presence of the Cys27 mutation did not suppress the 
prevention of the multimerization for M35 (i.e. M135 vs. M35), as it did for M3 (i.e. M13 vs. 
M3). 
As discussed above, the presence of the Cys27 mutation significantly enhances the 
multimerization (i.e. M13 vs. M3 and M1 vs. wild-type) presumably using Cys129 as the 
major bridging cysteine. Based on this observation, we hypothesize that the formation of the 
Cys27-Cys129 intramolecular disulfide bond in vitro might be thermodynamically or 
kinetically favorable [particularly in the presence of the Cys100 mutation (i.e. BL21(DE3)-
derived M3)], thus limiting the availability of free Cys129 for multimerization. Introducing the 
Cys27 mutation would free Cys129 and, as a result, multimerization enhanced. Also, notice 
that hCD83ext variants with the Cys27 mutation were less subject to degradation [89], 
implying that the formation of the Cys27-Cys129 disulfide bridge might destabilize the protein 
molecule.  
For all the hCD83ext mutant variants investigated in this study, there was a major 
conformational difference between the BL21(DE3)-derived and Origami B(DE3)-derived 
products based on the analyses with CD and fluorescence spectroscopy. By comparing the 
monomeric bands using non-reducing SDS-PAGE for M135 derived from the two hosts 
(Figure 8B), the conformational change should be associated with the formation of the Cys35-
Cys107 intramolecular disulfide bond. Though, as proposed above, the formation of the Cys35-
Cys107 intramolecular disulfide bond might not be thermodynamically or kinetically 
favorable in vitro, it could be rather effective in the oxidative cytoplasm of Origami B(DE3). 
In addition, the in vivo formed Cys35-Cys107 intramolecular disulfide bond significantly 
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enhanced in vitro multimerization since Origami B(DE3)-derived products (e.g. M3 and 
M13) tended to form multimers more effectively than their BL21(DE3)-derived counterparts. 
The multimerization associated with Origami B(DE3)-derived M3 and M13 was mediated 
through Cys129 since the multimerization was prevented by the presence of the Cys129 
mutation [i.e. Origami (DE3)-derived M3 vs. Origami B(DE3)-derived M35 and Origami 
B(DE3)-derived M13 vs. Origami B(DE3)-derived M135]. 
In summary, the mechanism of disulfide bond formation in hCD8ext was here 
elucidated. (1) Cys100 is critically but indirectly involved in the formation of intermolecular 
disulfide bonds for multimerization [Origami B(DE3)-derived M3 and two M13 variants 
develop multimerization]. (2) The presence of the Cys100 mutation prevents multimerization. 
Such prevention can be, however, suppressed by either the in vivo formation of the disulfide 
bond Cys35-Cys107 [Origami B(DE3)-derived M3 forms multimers] or by the introduction of 
the Cys27 mutation (two M13 variants form multimers). (3) Cys129 is primarily, possibly 
directly but not exclusively, engaged in the formation of intermolecular disulfide bonds for 
multimerization (I. M13 variants form dimers whereas M135 variants eliminate dimerization; 
II M5 forms dimers possibly linked via Cys100). (4) Cys27 might possibly form an 
intramolecular disulfide bond with Cys129 to prevent the multimerization which is enhanced 
by the presence of Cys100 mutation [BL21(DE3)-derived M3 eliminates multimerization vs. 
two M13 variants significantly develop multimerization]. (5) The presence of the Cys27 
mutation enhances multimerization, possibly via freeing Cys129 [I. M1 variants demonstrate 
increased multimerization compared to the wild-type variants; II. M13 variants display 
augmented multimerization compared to M3; III, M135 variants eliminate multimerization]. 
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(6) Cys35 and Cys107 are unlikely to participate in intermolecular disulfide bond formation; 
particularly in vitro (two M135 variants eradicate dimerization in vitro, even in the presence 
of free Cys35 and Cys107). (7) The formation of intramolecular disulfide bond between Cys35 
and Cys107 is peculiarly favored in vivo [Origami B(DE3)-derived M135 has 100% Cys35-
Cys107 bridged monomer vs. BL21(DE3)-derived M135 has an equilibrium between two 
monomeric isoforms (i.e. monomer with Cys35-Cys107 and monomer without Cys35-Cys107)]. 
(8) The in vivo formed Cys35-Cys107 results in conformational changes that enhance 
subsequent multimerization in vitro [the Origami B(DE3)-derived variants, wild-type, M1, 


















Conclusions and Recommendations 
8.1 Conclusions 
In this thesis, structural properties of hCD83ext produced by the developed bioprocess were 
studied. A series of cysteine mutant variants of hCD83ext were constructed to investigate the 
disulfide bond formation in this recombinant therapeutics. The following can be concluded: 
1. The disulfide bond formation significantly affects the structural property and 
biological activity of hCD83ext. While the established bioprocess produces 
hCD83ext product with high purity and low endotoxin level, inconsistent biological 
activity remains an issue, which primarily resulted from the lack of control on 
consistent disulfide bond formation. Therefore, modulation of disulfide bond 
formation is absolutely necessary in the production and extensive storage of the 
protein.  
2. Aberrant intermolecular disulfide bond formation in the hCD83ext should be 
prevented to display consistent biological activity. Cys129 is the one primarily and 
directly involved in intermolecular disulfide bond formation. However, the impacts of 
Cys100 and Cys27 on intermolecular disulfide bond formation are very important, 
although they do not tend to participate directly. 
3. The strategy of using E. coli Origami strain as a host to facilitate disulfide bond 
formation in vivo is proven not helpful for hCD83ext production. Aberrant disulfide 
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bond formation occurs in vivo, and subsequently aggravates the intermolecular 
disulfide bond formation in hCD83ext and its mutant variants. On the other hand, 
rational site-directed mutagenesis on cysteine residues is a more attractive approach. 
hC83ext mutant variant M3 with Cys100Ser was identified as an improved version of 
the therapeutic since it consistently displayed excellent biological activity.  
4. The storage stability of hCD83ext can be altered by manipulating disulfide bond 
formation. Mutating Cys27 to Ser or Glu significantly enhanced the stability.  
5. Environment significantly affects the disulfide bond formation in hCD83ext, reflected 
by the differences constantly demonstrated between in vivo and in vitro disulfide 
bond formation in hCD83ext and its mutant variants.  
 
8.2 Recommendations 
The thesis presents some new understanding of the structural properties of hCD83ext. The 
following is recommended for future work to further improve the performance of production. 
1. The mechanism underlying the elimination of multimerization in BL21(DE3)-derived 
M3 was assumed to be the formation of intramolecular disulfide bond Cys27-Cys129. 
To solidly prove this assumption, effective methodology for disulfide bond 
assignment needs to be developed. Further, disulfide bond patterns that are possibly 
beneficial for biological activity development needs to be elucidated. In addition, the 
application of this methodology to the wild-type hCD83ext and the M1 will help to 
reveal the mechanism by which Cys27 mutation stabilizes hCD83ext.  
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2. hCD83ext derived by BL21 and Origami strains exhibited distinctive molecular 
properties commitment with in vivo disulfide bond formation, implying that 
hCD83ext might undergo a disulfide-coupled oxidative folding pathway. Therefore, 
reductive unfolding followed by oxidative folding may be good to carry out for 
hCD83ext and its mutant variants to learn more details on disulfide bond formation of 
hCD8ext and the role of each cysteine residue. The investigation of folding pathway 
might shed light on the development of effective strategies to promote consistent 
disulfide bond formation in hCD83ext.  
3. Although oxidative cytoplasmic expression of the fusion GST-hCD83ext was not 
helpful in consistent disulfide bond formation, it is worthy of developing periplasmic 
expression or extracellular secretion of hCD83ext in E. coli. The native disulfide 
bond formation pathway might better facilitate disulfide bond formation in 
hCD83ext. Furthermore, a wide variety of well-established strategies can be adopted 




DNA sequencing results and alignment 
The DNA sequence alignment was conducted using NCBI BLASTN program accessible at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_PROGRAMS=megaBl
ast&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome.  
The Query is the sequence of constructed hCD83ext mutant obtained from DNA sequencing. 
The Sbjct (Subject) is the sequence of wild-type hCD83ext. The designated nucleotidic 
mutations are highlighted in green. The mutation automatically arising during PCR cycles is 
highlight in yellow, which is a silent mutation. 
 
Aa1. Alignment of the DNA sequences of hCD83ext_mut_C27S and the hCD83ext 
 
Query 43  AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC 102 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 378 AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC 319 
 
Query 103 TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT 162 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 318 TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT 259 
 
Query 163 GTATGTCCCCGAGTTGCAGCTGGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT 222 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 258 GTATGTCCCCGAGTTGCAGCTGGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT 199 
 
Query 223 GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCCCTGAGGTGGTC 282 
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct 198 GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCTCTGAGGTGGTC 139 
 
Query 283 TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT 342 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query 343 GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGAGCTCGC 402 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  || 
Sbjct 78  GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGAGCAAGC 19 
 
Query 403 CACCTTCACCTCCGGCGT 420 
          |||||||||||||||||| 





Aa2. Alignment of DNA sequences of hCD83ext_mut_C27E and hCD83ext 
 
Query 39  AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC 98 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 378 AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC 319 
 
Query 99  TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT 158 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 318 TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT 259 
 
Query 159 GTATGTCCCCGAGTTGCAGCTGGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT 218 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 258 GTATGTCCCCGAGTTGCAGCTGGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT 199 
 
Query 219 GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCCCTGAGGTGGTC 278 
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct 198 GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCTCTGAGGTGGTC 139 
 
Query 279 TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT 338 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 138 TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT 79 
 
Query 339 GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGACTCAGC 398 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||   ||| 




Query 399 CACCTTCACCTCCGGCGT 416 
          |||||||||||||||||| 




Aa3. Alignment of the DNA sequences of hCD83ext_mut_C100S (M3) and hCD83ext 
 
Query  44   AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC  103 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  378  AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC  319 
 
Query  104  TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT  163 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  318  TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT  259 
 
Query  164  GTATGTCCCCGAGTTGGAGCTCGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT  223 
            |||||||||||||||| |||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  258  GTATGTCCCCGAGTTGCAGCTGGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT  199 
 
Query  224  GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCCCTGAGGTGGTC  283 
            |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  198  GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCTCTGAGGTGGTC  139 
 
Query  284  TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT  343 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  138  TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT  79 
 
Query  344  GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGAGCAAGC  403 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78   GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGAGCAAGC  19 
 
Query  404  CACCTTCACCTCCGGCGT  421 
            |||||||||||||||||| 





Aa4. Alignment of the sequenced DNA of hCD83ext_mut_C27S_C100S (M13) and the 
DNA of hCD83ext 
 
Query 43  AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC 102 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 378 AATCTCCGCTCTGTATTTCTTAAAAGTCTCTTCTTTACGCTGTGCAGGGCATCCTGTCAC 319 
 
Query 103 TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT 162 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 318 TCTCAAGATCACCTTGCCACTTAGGTTTCTCTGCCCATCCGGGTCCTGCAGAGTGCACCT 259 
 
Query 163 GTATGTCCCCGAGTTGGAGCTCGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT 222 
          |||||||||||||||| |||| |||||||||||||||||||||||||||||||||||||| 
Sbjct 258 GTATGTCCCCGAGTTGCAGCTGGTAGTGTTTCGGATCTTCAGGGAATAGGGCCTTTCATT 199 
 
Query 223 GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCCCTGAGGTGGTC 282 
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct 198 GGGGGCGTCGAAAGAACCATTTTGCCCCTTCTGATGATAGTGCTGTCCTCTGAGGTGGTC 139 
 
Query 283 TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT 342 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 138 TTCCTGGGGTGTCTCCATCCTCTCTTCACCACCCTCCAATAACTTGACCCAGGAGACCGT 79 
 
Query 343 GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGAGCTCGC 402 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  || 
Sbjct 78  GTAGGGAACCTGCGGATCCCAGGGGGCGGTGCAGGGCAAGTCCACATCTTCGGAGCAAGC 19 
 
Query 403 CACCTTCACCTCCGGCGT 420 
          |||||||||||||||||| 












Aa5. Alignment of the DNA sequences of hCD83ext_mut_C27S_C100S_C129S (M135) and 
hCD83ext 
 
Query 1   ACGCCGGAGGTGAAGGTGGCTTGCTCCGAAGATGTGGACTTGCCCTGCACCGCCCCCTGG 60 
          ||||||||||||||||||||  |||||||||||||||||||||||||||||||||||||| 
Sbjct 420 ACGCCGGAGGTGAAGGTGGCGAGCTCCGAAGATGTGGACTTGCCCTGCACCGCCCCCTGG 361 
 
Query 61  GATCCGCAGGTTCCCTACACGGTCTCCTGGGTCAAGTTATTGGAGGGTGGTGAAGAGAGG 120 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 360 GATCCGCAGGTTCCCTACACGGTCTCCTGGGTCAAGTTATTGGAGGGTGGTGAAGAGAGG 301 
 
Query 121 ATGGAGACACCCCAGGAAGACCACCTCAGAGGACAGCACTATCATCAGAAGGGGCAAAAT 180 
          ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
Sbjct 300 ATGGAGACACCCCAGGAAGACCACCTCAGGGGACAGCACTATCATCAGAAGGGGCAAAAT 241 
 
Query 181 GGTTCTTTCGACGCCCCCAATGAAAGGCCCTATTCCCTGAAGATCCGAAACACTACCAGC 240 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct 240 GGTTCTTTCGACGCCCCCAATGAAAGGCCCTATTCCCTGAAGATCCGAAACACTACGAGC 181 
 
Query 241 TGCAACTCGGGGACATACAGGTGCACTCTGCAGGACCCGGATGGGCAGAGAAACCTAAGT 300 
          | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 180 TCCAACTCGGGGACATACAGGTGCACTCTGCAGGACCCGGATGGGCAGAGAAACCTAAGT 121 
 
Query 301 GGCAAGGTGATCTTGAGAGTGACAGGATGCCCTGCACAGCGTAAAGAAGAGACTTTTAAG 360 
          |||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||| 
Sbjct 120 GGCAAGGTGATCTTGAGAGTGACAGGATCCCCTGCACAGCGTAAAGAAGAGACTTTTAAG 61 
Query 361 AAATACAGAGCGGAGATT 378 
          |||||||||||||||||| 




Metropolis-Hastings algorithm used for parameter estimation of 
dimerization reactions of mutant variants hCD83ext_mut_C27E and 
hCD83ext_mut_C27S 
 
Kinetic modeling often requires parameter estimates by some statistical methods. Metropolis-   
Hastings algorithm, one of Markov Chain Monte Carlo (MCMC) methods, has been found to 
be a very powerful tool, especially when some prior knowledge about the parameters is 
available. This method is applicable to any set of observations that conform to a Markov 
chain. The algorithm has been employed to solve difficult, non-linear parameter estimation 
problems arising in various disciplines. It involves one parameter at a time sampling and 
iteration to find the posterior parameter distribution. 
Let us assume that y1, y2, y3…yn-1, yn are independent observations that have been 
collected in a temporal or physical space. These observations are said to form a Markov chain 
if the following conditional probability is obeyed: 
 
P(yn| y1, y2,…yn-2, yn-1) = P(yn| yn-1) 
 
Thus the probability of obtaining the current observation (i.e. observation “n”) is conditional 
on only the previous (i.e. penultimate) observation (“n-1”). A number of data sets resulting 




chain observations. The Metropolis-Hastings algorithm is then fully incorporated into the 
LAKEVIEW program.  
A set of parameters θ (i.e. θ1, θ2, θ3 etc.) that needs to be estimated given the set of 
observations, y. The Bayesian inference of model parameters θ given the observed data 
involves the joint posterior probability distribution conditional on the data P(θ | y). 
According to Bayes’ theorem, the joint probability of θ given y is: 
 
 P(θ | y) ∝ P(θ) P(y | θ) 
 
where: 
P(θ) = prior distribution of  the parameters 
P(y | θ) = likelihood function conditional on θ.  
 
The calculation procedure is based on the Gibbs sampling version of the Metropolis-Hastings 
algorithm. The Metropolis-Hastings algorithm for parameter estimation can be summarized 
as follows: 
a) Assign prior probability distribution J(θn | θn-1) for each parameter to be estimated. 
b) Obtain θ(0) as the initial realization of the parameter vector. 
c) Sample the proposed distribution J(θn | θn-1) to obtain parameter value θ*. 















            set     θn = θ* with probability min (r, 1) 
                     θn = θn-1 otherwise  
e) Continue obtaining realizations of θn for n = 1, 2, 3, N until P(θn | y) converges to P(θ 
| y). 
In the LAKEVIEW model, each parameter to be estimated is assigned a triangular a 
priori distribution, J(θn|θn-1), containing the maximum, mean (most likely) and the minimum 
possible values. The mean value is established either by graphical means or "eyeballing" the 
experimental data.  The obvious advantage of choosing a symmetric prior distribution such as 









The parameter distribution space is sampled and a given parameter value is assigned by a 
Monte Carlo draw. Using the sampled value, the predicted concentrations are computed by 
integrating the differential equations. The predictions are then compared with measurements 
by calculating the normalized sum of squares between the observations and predictions. In 
LAKEVIEW, the normalized squared differences are calculated between predictions and 





repeated a number of times. Both the new parameter and its value are chosen by random 
draw using the Monte Carlo technique.  
The objective of the parameter estimation is to minimize the sum of squared 
differences between predicted and observed dependent variables. A “benchmark” conditional 
model probability is calculated after substituting the expected parameter values θmean = E(θIi) 
into the differential equations and integrating to give the predicted dependent variable 
y(θmean,t): 
 










−∝ e  
where: 
p(y|θ,mean) = conditional “baseline” model probability 
y(θmean,tk) = model prediction using expected parameter values at time tk 
y(tk)  = observation taken at time tk 
nt  = total number of observations 
σ2  = variance 
 
Using Bayesian inference, the posterior probability is given by: 
 






P(θmean | y) = "benchmark" predictive model probability for a given set of  
      observations, yk 
p(θ,mean)  =  the probability of selecting parameter set θ,mean 
 
It is evident that minimizing the sum of squared differences between predictions and 
observations implies maximizing the probability P(θmean | y). The posterior probability is re-
calculated after each parameter selection.  
The sampling space consists of n trials and a maximum of m iterations per trial. This 
leads to a maximum of n x m parameter selection.  The number of trials (the value of “n”) 
should be at least 100 resulting in a set (θ1, θ2, θ3 etc.) of 100 parameter estimates.  The 
number of iterations is based on the number of parameters to be estimated.  As a rule of 
thumb, the number of draws should be about 10 for each parameter.  Thus, the total number 
of iterations per trial, m, should be about tenfold the number of parameters to be estimated. 
The first trial commences with the calculation of the benchmark (or baseline probability) 
with the expected parameter values, E(θi)-s. Then the selection of the parameter, say 
parameter "i" and its value (θi) is performed by random draw as described above. Model 
probability with the selected value, θi is given as: 
 

















−∝ e  
where: 
θI = most recently drawn parameter value 
 
It should be noted that the Metropolis-Hastings algorithm is quite flexible and the posterior 
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If the probability min{r, 1} for equation (Ab-4) is satisfied with respect to the benchmark 
value in trial 1, then P(θi| y) becomes a "first" estimate of a "global probability maximum", 
P(θg |y). 
In applying the Metropolis-Hastings algorithm for parameter estimation in the present 
case, 9,000 to 30,000 trials were performed using each set of data. The first 1/3 of the trials 
(3,000 – 10,000) were used for burn-in. During this burn-in period model variance was 
estimated in the following manner:  












Parameter acceptance and storage begins after this initial trial period. After storing the 
accepted parameter values, the parameters are reset to their expectations (E(θ)) and a new 
trial begins. Alternatively, the selected parameter values are replaced and the draw may 
continue until the number of trials, n, is exceeded. At this point the parameters are also reset 
to E(θ)-s and a new trial begins. In subsequent trials, if the probability P(θi| y) is greater than 
the benchmark probability, but less than the current global probability, then the drawn 
parameter θi is retained and is used in subsequent iterations within the trial as a starter value. 
If, however, the probability P(θI | y) is less than the benchmark probability then θi is replaced 
by previous estimate. An accelerated search technique allows the parameters corresponding 
to interim P(θ |y) to become the benchmark parameters (new E(θi)-s by centering the 
triangular distribution on the best current estimate of θg) after a certain number of 
unsuccessful trials (i.e. trials in which the number of iterations exceeds "m"). This is 
performed once after a number of “training” trials (1/3 of the total number of trials). In this 
case, the “bins” for storing the accepted θ-s is established after the initial number of 
“training” trials. If needed, the triangular parameter range (i.e. θmax and θmin) is adjusted to 
maintain symmetry. This adjustment becomes necessary whenever the current best parameter 
value approaches but cannot be less than zero.    
A difficult problem remains the need to estimate the marginal posterior density for 
the parameter set θ: 




It is well known that the posterior density for θ possesses a multivariate normal distribution, 
but the performance of the integration analytically is far too difficult. An acceptable 
empirical solution is to save the set of θ-s after the training trials. The argument is that, if the 
maximum trial number “n” is chosen large enough, then the parameters have converged (or 

















σi2 = variance of parameter “i” 
θi,j  = the parameter value of type “i” in the j th data set (η-k <= j <=η) 
θi,mean = the average value of parameter “i” 
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